



**HAL**  
open science

## An enquiry to the role of CB1 receptors in neurodegeneration

Ignacio Fernandez-Moncada, Abel Eraso-Pichot, Tommaso Dalla Tor,  
Berenice Fortunato-Marsol, Giovanni Marsicano

► **To cite this version:**

Ignacio Fernandez-Moncada, Abel Eraso-Pichot, Tommaso Dalla Tor, Berenice Fortunato-Marsol, Giovanni Marsicano. An enquiry to the role of CB1 receptors in neurodegeneration. *Neurobiology of Disease*, 2023, 184, 10.1016/j.nbd.2023.106235 . hal-04488088

**HAL Id: hal-04488088**

**<https://hal.science/hal-04488088>**


Submitted on 4 Mar 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0  
International License



## An enquiry to the role of CB1 receptors in neurodegeneration

Ignacio Fernández-Moncada<sup>a,\*</sup>, Abel Eraso-Pichot<sup>a</sup>, Tommaso Dalla Tor<sup>a,b</sup>,  
Béatrice Fortunato-Marsol<sup>a</sup>, Giovanni Marsicano<sup>a,\*</sup>

<sup>a</sup> Université de Bordeaux, INSERM, Neurocentre Magendie, U1215, F-33000 Bordeaux, France

<sup>b</sup> Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania 95124, Italy

### ARTICLE INFO

#### Keywords:

CB1 receptor  
Cannabinoids  
Alzheimer  
Parkinson  
Huntington

### ABSTRACT

Neurodegenerative disorders are debilitating conditions that impair patient quality of life and that represent heavy social-economic burdens to society. Whereas the root of some of these brain illnesses lies in autosomal inheritance, the origin of most of these neuropathologies is scantily understood. Similarly, the cellular and molecular substrates explaining the progressive loss of brain functions remains to be fully described too. Indeed, the study of brain neurodegeneration has resulted in a complex picture, composed of a myriad of altered processes that include broken brain bioenergetics, widespread neuroinflammation and aberrant activity of signaling pathways. In this context, several lines of research have shown that the endocannabinoid system (ECS) and its main signaling hub, the type-1 cannabinoid (CB1) receptor are altered in diverse neurodegenerative disorders. However, some of these data are conflictive or poorly described. In this review, we summarize the findings about the alterations in ECS and CB1 receptors signaling in three representative brain illnesses, the Alzheimer's, Parkinson's and Huntington's diseases, and we discuss the relevance of these studies in understanding neurodegeneration development and progression, with a special focus on astrocyte function. Noteworthy, the analysis of ECS defects in neurodegeneration warrant much more studies, as our conceptual understanding of ECS function has evolved quickly in the last years, which now include glia cells and the subcellular-specific CB1 receptors signaling as critical players of brain functions.

### 1. (Endo)Cannabinoid signaling in the brain

For centuries, the *Cannabis sativa* plant has been used for different purposes, such as for providing fibers, food, and oil, for recreational and religious purposes, but most interestingly it has been intensely used as a medicine (Bonini et al., 2018). The main psychoactive component of cannabis  $\Delta^9$ -tetrahydrocannabinol (THC) is responsible for the psychotropic effects associated with cannabis consumption. However, THC also seems to be involved in the potential therapeutic effects of cannabis use (Baker et al., 2003; Dos Santos et al., 2021; Fraguas-Sánchez and Torres-Suárez, 2018). Interestingly, THC possesses several pro-therapeutic effects, for example it can reduce nociception (i.e., reduce pain sensation), stimulate the appetite, diminish nausea/vomits or act as anticonvulsant (Baker et al., 2003; Dos Santos et al., 2021; Fraguas-Sánchez and Torres-Suárez, 2018). These THC-mediated effects might support its therapeutic use for the treatment of many pathologies including epilepsy, neuropathic pain, cancer and neurodegenerative disorders (Baker et al., 2003; Gordon and Devinsky, 2001; Pacher et al., 2006; Walsh et al.,

2003). However, THC consumption is accompanied by impairment of diverse brain functions, such as catalepsy or acute impairment of attention, learning and memory (Stella, 2023). Remarkably, these negative effects are enhanced when consuming *Cannabis* that contains higher amounts of THC. Of note, the potential therapeutic or toxic effects of THC consumption might also depend on the presence of other cannabinoids compounds contained in *Cannabis sativa*, which are so far less studied (Dos Santos et al., 2021; Stella, 2023). Therefore, to better understand both the positive and negative effects of THC, several studies over the past decades have focused on determining the cellular and molecular mechanisms that underline the various effects of THC on bodily functions.

The isolation of THC from *Cannabis sativa* (Gaoni and Mechoulam, 1964; Wollner et al., 1942) pave the way to the discovery of the endocannabinoid system (ECS), a complex endogenous modulatory signaling system that is targeted by both endogenous and exogenous cannabinoids (Martinez Ramirez et al., 2023; Zou and Kumar, 2018). Remarkably, the ECS is largely distributed in diverse tissues, including the brain

\* Corresponding authors.

E-mail addresses: [ignacio.fernandez-moncada@inserm.fr](mailto:ignacio.fernandez-moncada@inserm.fr) (I. Fernández-Moncada), [giovanni.marsicano@inserm.fr](mailto:giovanni.marsicano@inserm.fr) (G. Marsicano).

<https://doi.org/10.1016/j.nbd.2023.106235>

Received 3 April 2023; Received in revised form 27 June 2023; Accepted 20 July 2023

Available online 21 July 2023

0969-9961/© 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

(Martínez Ramírez et al., 2023), muscle, adipose tissue or reproductive organs (Kamnate et al., 2022; Kano et al., 2009; Mendizabal-Zubiaga et al., 2016; Pagano Zottola et al., 2022; Rossato et al., 2005), and it is involved in distinct physiological functions such as whole-body energy handling and storage, cardiac function, pain control and reproduction, amongst many others (Busquets-García et al., 2022; Fonseca and Rebelo, 2022; O'Keefe et al., 2014; Piazza et al., 2017; Sierra et al., 2018; Woodhams et al., 2015). The ECS is composed the G-protein coupled receptors (GPCRs) type-1 and type-2 cannabinoid receptors (CB1 and CB2 receptors, respectively), by their endogenous lipid ligands anandamide (AEA) and 2-arachidonoyl-glycerol (2-AG), the so-called endocannabinoids (eCBs), and by the enzymes responsible for eCBs synthesis and degradation. Interestingly, a wide range of enzymes participates in the biosynthesis and degradation of eCBs. These include N-acyl-phosphatidylethanolamine-specific phospholipase D (NAPE-PLD),  $\alpha/\beta$ -hydrolase domain type-4 (Abd4), glycerophosphodiesterase-1 (GDE1), protein tyrosine phosphatase N22 (PTPN22) for AEA biosynthesis, and diacylglycerol lipase- $\alpha$  or - $\beta$  (DAGL $\alpha$  and DAGL $\beta$ ) for 2-AG biosynthesis. In the other hand, eCBs degradation also is carried out by specific enzymes, with fatty acid amide hydrolase-1 (FAAH) being responsible for AEA degradation, while monoacylglycerol lipase (MAGL),  $\alpha/\beta$ -Hydrolase Domain Containing Protein 6 and 12 (ABDH6 and 12), and FAAH-1 are involved in 2-AG degradation (Cristino et al., 2020; Iannotti et al., 2016; Martínez Ramírez et al., 2023; Zou and Kumar, 2018). Notably, and in contrast to conventional vesicle-stored neurotransmitters, eCBs are generally believed to be synthesized and released on demand. The production of eCBs is controlled via intracellular calcium increases, caused by activation of specific GPCRs or secondary to plasma membrane depolarization in excitable cells, which stimulates the enzymes involved in eCBs synthesis, resulting in their mobilization to activate cannabinoid receptors (Cristino et al., 2020; Iannotti et al., 2016; Piomelli, 2003). In the central nervous system, the ECS governs key brain functions, such as emotional regulation, feeding behaviors and cognition via the CB1 receptors signaling (Busquets-García et al., 2018; Busquets-García et al., 2022; Piazza et al., 2017). Noteworthy, these receptors are expressed across the entire brain parenchyma (Kano et al., 2009), and in diverse brain cell-types, such as neurons, microglia, oligodendrocytes and astrocytes (Eraso-Pichot et al., 2023; Marinelli et al., 2023; Martínez Ramírez et al., 2023; Molina-Holgado et al., 2023). However, the CB1 receptor-mediated intracellular signaling differs between specific brain cells. For instance, neuronal CB1 receptors are typically coupled to G<sub>i</sub>/G<sub>o</sub> proteins, that in turn inhibit adenylyl cyclase (AC) and specific voltage-dependent calcium channels. In parallel, CB1 receptor signaling activates mitogen-activated protein kinases (MAPKs) and rectifying potassium channels (Alger, 2002; Araque et al., 2017; Howlett, 2002). Ultimately, these signaling cascades inhibit synaptic function and reduce neurotransmitter release (Araque et al., 2017). Conversely, astroglial CB1 receptors have been suggested to couple to G<sub>q/11</sub>, and their engagement triggers intracellular calcium increases, which in turn modulates the astrocyte control of synaptic function (Han et al., 2012; Martín et al., 2015; Navarrete and Araque, 2008, 2010; Robin et al., 2018; Serrat et al., 2021).


Remarkably, CB1 receptors can be functionally associated to mitochondrial membranes (mtCB1 receptor) (Benard et al., 2012; Hebert-Chatelain et al., 2014, 2016; Jimenez-Blasco et al., 2020; Koch et al., 2015; Mendizabal-Zubiaga et al., 2016; Pagano Zottola et al., 2022; Soria-Gomez et al., 2021), thus defying the dogma of strict plasma membrane localization of most of GPCRs. Importantly, pharmacological mtCB1 receptors activation inhibits mitochondrial functions and determines diverse negative effects associated to cannabinoid exposure, such as catalepsy (Soria-Gomez et al., 2021), impaired cognitive performance (Hebert-Chatelain et al., 2016) and diminished social interaction (Jimenez-Blasco et al., 2020). In particular, it has been observed that activation of mtCB1 receptors by either endogenous or exogenous cannabinoids inhibits mitochondrial respiration and energy production. This phenomenon involves intra-mitochondrial G<sub>i/o</sub> protein signaling

and inhibition of soluble adenylyl cyclase (sAC). This causes a reduction in cyclic AMP levels and protein kinase A activity, which in turn reduces the phosphorylation of specific subunits of the mitochondrial complex I (such as NDUFS2 and NDUFS4). Ultimately, this reduces complex activity and stability and causes a decrease in mitochondrial respiration (Benard et al., 2012; Hebert-Chatelain et al., 2016; Jimenez-Blasco et al., 2020; Soria-Gomez et al., 2021). Noteworthy, mtCB1 receptors are not found only in neurons (Benard et al., 2012; Hebert-Chatelain et al., 2014; Koch et al., 2015; Soria-Gomez et al., 2021), but also in astrocytes (Gutiérrez-Rodríguez et al., 2018; Jimenez-Blasco et al., 2020; Serrat et al., 2021), where they diminish glycolytic activity, causing an inhibition of lactate production, that impairs social behavior after 24 h of cannabinoids exposure (Jimenez-Blasco et al., 2020). Moreover, mtCB1 receptors also control the endoplasmic reticulum-mitochondria calcium transfer to modulate astrocyte-mediated control of synaptic activity (Serrat et al., 2021). Overall, CB1 receptors exert a complex modulatory function, involving cell-type specific and subcellular compartmentalized signaling, which ultimately control brain function and behavior (Busquets-García et al., 2018; Busquets-García et al., 2022; Martínez Ramírez et al., 2023) (Fig. 1).

Significantly, altered CB1 receptors signaling has been observed in diverse neurodegenerative disorders that affect both the central and peripheral nervous system (Cristino et al., 2020; Paes-Colli et al., 2022; Vasincu et al., 2022). Importantly, CB1 receptors are not the only cannabinoid-related elements linked to neurodegenerative conditions. For instance, (endo)cannabinoids can activate also CB2 receptors or other targets (e.g., transient receptor potential channels), and all these processes might play roles in neurodegenerative disorders (Agarwal et al., 2017; Cristino et al., 2020; Hong et al., 2020; Vasincu et al., 2022). Nevertheless, CB1 receptors are the main studied elements of the ECS in the context of neurodegeneration and will be the focus of the present review article. Moreover, many reviews have addressed the role of CB1 receptors in neurodegenerative disorders without dealing in depth with the potential roles of specific cell-types or implicitly focusing on neuronal mechanisms (Basavarajappa et al., 2017; Cristino et al., 2020; Vasincu et al., 2022). Therefore, in the context of the present special issue, this article will specifically focus on the impact of astroglial CB1 receptors signaling on the pathogenesis of certain neurodegenerative diseases. For this purpose, we will focus on three common and well-studied neurodegenerative disorders that affect the central nervous system: Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD).

## 2. Altered ECS signaling in AD

AD is a highly prevalent neurodegenerative disease, affecting millions of people worldwide. Its incidence is expected to grow during the coming years, mostly due to the prolonged lifespan (GBD 2016 Dementia Collaborators, 2019; Knopman et al., 2021). AD is also the most common form of dementia, and is characterized by cognitive decline, as well as functional impairment in daily living activities (Alzheimer's disease facts and figures, 2023.; Knopman et al., 2021). At the histopathological level, the hallmarks of AD are cerebral atrophy, the extracellular accumulation of amyloid- $\beta$  peptide (A $\beta$ ) in plaques, and the intracellular accumulation of neurofibrillary tangles of hyperphosphorylated tau protein. In addition, some other pathological hallmarks appear during the progression of the disease, such as brain inflammation, oxidative stress, metabolic failure, excitotoxicity and neurodegeneration (Heneka et al., 2015; Knopman et al., 2021). Since AD discovery (Hippius and Neundörfer, 2003), much effort has been devoted to identifying the molecular mechanisms explaining the pathogenesis and development of the disease, in order to improve both the diagnosis and therapy. Importantly, few treatments exist and most of them do not target the progression of the disease. Furthermore, several strategies to stop AD progression have failed in the clinical stages or present a low efficacy (Asher and Priefer, 2022; Fillit and Green, 2021).



**Fig. 1.** Cellular and subcellular CB1 receptor signaling in astrocytes and neurons.

During neurotransmission, activation of postsynaptic neurons by neurotransmitters (NT) released by presynaptic neurons, causes an increase in endocannabinoids (eCBs) synthesis and release. The binding of eCBs to plasma membrane CB1 receptors in presynaptic neurons, activate  $G_{i/o}$  protein signaling cascade that blocks the neurotransmitter release. In particular, CB1-dependent signaling in neurons result in reduction of adenylate cyclase (AC) activity, decreased cyclic AMP (cAMP) levels and activation of different kinases, as for example mitogen-activated protein kinases (MAPKs), phosphoinositide 3-kinase (PI3K) and protein kinase B (Akt). Importantly, CB1 receptors are also present in astrocytes, and their activation triggers  $G_q$  protein signaling and causes a  $Ca^{2+}$  level increase and promotes the release of gliotransmitters. Remarkably, CB1 receptors are also found in subcellular compartments, such as the mitochondria (mtCB1). Engagement of mtCB1 receptors pool inhibits the soluble AC (sAC) and diminishes the cAMP and PKA activity, thereby reducing complex I activity and mitochondrial respiration. This phenomenon reduces neuronal energy availability and impairs NT release. Interestingly, astroglial mtCB1 receptors activation diminishes mitochondria respiration, but also decrease HIF1 levels which impairs the glycolytic activity and reduce the lactate production.

As stated above, during AD progression, alterations in multiple and diverse biological systems have been discovered. Interestingly, one of the systems that seems to be altered is the ECS and consequently the CB1 receptor-dependent signaling. Some components of the ECS have been found to be altered in AD patients, including the enzymes that metabolize eCBs (Berry et al., 2020). For instance, whereas cortical AEA levels are decreased in AD patients and these inversely correlate with  $A\beta_{42}$  levels and cognitive symptoms (Jung et al., 2012), in the hippocampus the activity of 2-AG degrading enzymes is increased (Mulder et al., 2011), which might promote aberrant 2-AG levels and CB1 receptor activity.

Regarding animal studies, several different mouse models of AD exist, each one recapitulating specific aspects of the disease (Götz et al., 2018; Mckean et al., 2021). These mutant mouse models usually consist in the overexpression of different mutated forms of the human amyloid beta precursor protein (APP) often in combination with overexpression of human mutated forms of the Presenilin 1 (PS1) protein, which is the enzyme responsible of APP cleaving and thus  $A\beta$  production. Overexpression of these mutated proteins induces more  $A\beta$  production and aggregation and is able to recapitulate some disease features. However, different mutations will differently affect the disease progression and the age of the mice is key to compare between different disease models.

Interestingly, some of these AD models have shown some alterations of ECS members. In particular, the 5xFAD AD mouse model, which overexpress both human APP carrying three Familial AD (FAD) mutations and human PS1 harboring two FAD mutations, showed increased hippocampal levels of the 2-AG producing enzyme DAGL $\alpha$  (Medina-Vera et al., 2020). Conversely, in the APP/PS1 mouse model, which also overexpresses the two human proteins harboring one mutation each, the mRNA level of DAGL $\alpha$  mRNA was reduced in the prefrontal cortex and cerebellum of pre symptomatic male mice (Vidal-Palencia et al., 2022). These contradictory results may be explained by the differences between the brain areas analyzed, the mouse models used or the stage of the disease. Also, it is important to take into account the possible sexual dimorphism observed both in AD and responses to cannabinoids. For instance, both women and female mice display increased pathological AD hallmarks (Fisher et al., 2018; Jiao et al., 2016) as well as increased sensitivity to some THC-induced effects (Blanton et al., 2021; Calakos et al., 2017; Rubino and Parolaro, 2011) although CB1 availability seems to be reduced (Laurikainen et al., 2019), which add another degree of complexity in the interpretation of these results (Vidal-Palencia et al., 2022).

Studies addressing the expression of CB1 receptor and its downstream signaling in AD patients are also not conclusive. Some studies

point to a reduction in the expression and signaling of CB1 receptors in the cortex of symptomatic AD patients (Ramírez et al., 2005; Solas et al., 2013), although others did not find differences in these parameters in the cortex and hippocampus (Ahmad et al., 2014; Lee et al., 2010; Mulder et al., 2011). Interestingly, some studies have found increased CB1 expression and/or activity in some brain areas only during early stages of the disease (Farkas et al., 2012; Manuel et al., 2014) (Table 1). In AD mouse models, the CB1 receptor expression or signaling were found to be altered in a region-specific fashion, depending on the mouse model used and the stage of the disease (Bedse et al., 2014; González de San et al., 2021; Kalifa et al., 2011; Maccarrone et al., 2018; Medina-Vera et al., 2020; Takkinen et al., 2018; Vidal-Palencia et al., 2022) (Table 2). Importantly, most of these works addressed the expression of CB1 receptors without dissecting the expression in different brain cell types. However, recently it has been shown that CB1 is upregulated in reactive microglia in 5xFAD AD model (Terradillos et al., 2023), which might partially explain the differences in CB1 receptor expression in AD mouse models.

The alterations at the levels of ECS components, specially CB1 receptors, suggested that the ECS might represent a potential target in the treatment of AD (Abate et al., 2021; Páez and Campillo, 2019; Talarico et al., 2019). Of note, the deletion of CB1 receptors in different AD mouse models results in further impairment of cognitive functions (Aso et al., 2018; Stumm et al., 2013), thus suggesting a protective role of the ECS in the development of AD-like symptoms in mouse models. In this context, the targeting of CB1 receptors with exogenous cannabinoids might be a promising therapeutical avenue to slow down AD progression. For instance, exposure to THC is able to significantly reduce brain inflammation in the APP/PS1 mice (Aso et al., 2015), and chronic treatment with a mix of the phytocannabinoids THC and cannabidiol (CBD) improves the memory impairment in advanced stages of AD pathology in mice (Aso et al., 2016). Remarkably, THC treatment was able to decrease amyloid plaques level in the 5xFAD APP mouse model by increasing A $\beta$  degradation via neprilysin activity (Chen et al., 2013).

Similarly, synthetic CB1 receptor agonists have also been found to modify AD progression. Chronic administration of arachidonyl-2-chloroethylamide (ACEA) in the A $\beta$ PP(swe)/PS1(1dE9) transgenic mice, either at the pre-symptomatic or early symptomatic stages, improve mice cognitive impairment (Aso et al., 2012). Moreover, ACEA treatment can prevent the cognitive impairment induced by hippocampal infusion of A $\beta$ <sub>(25–35)</sub> (Patricio-Martínez et al., 2019). Finally, increasing the eCBs tone via pharmacological or genetic inhibition of eCBs degrading enzymes has also been shown to be a promising therapy for AD (Abate et al., 2021; Chen et al., 2012; Piro et al., 2012; Ruiz-Pérez et al., 2021), thus confirming the beneficial effects of modulating the ECS in AD. Nevertheless, the role of CB1 receptor signaling as potential therapeutic treatment for AD warrant further studies, especially its associated cellular and molecular mechanisms. In this context, the neuroinflammation and excitotoxicity observed in AD (Talarico et al., 2019), are two well-known processes targeted by CB1 receptors in neurons and other cell types (Aso and Ferrer, 2014; De Meij et al., 2021; Eraso-Pichot et al., 2023). Thus, further studies in this area might deliver interesting data.

Finally, several studies have established that metabolic alterations are part of the AD pathology. For instance, many investigations have demonstrated a reduction in brain glucose uptake in specific brain areas, both in patients and mouse models (Demetrius and Driver, 2013; Ferreira et al., 2010; Mosconi et al., 2009; Weise et al., 2018). Interestingly, astrocytes have a prominent role in the control of brain glucose consumption (Beard et al., 2021; Bélanger et al., 2011; Weber and Barros, 2015), and some studies have already suggested that astrocyte malfunction might be the main factor explaining the reduced brain glucose metabolism in AD (Newington et al., 2013; Zulfqar et al., 2019). As an example, astrocytic glucose transporter GLUT1 is reduced both in AD brains and in cultured astrocytes from arcA $\beta$  mice (Merlini et al., 2011; Simpson et al., 1994), which might reduce the brain glucose uptake capacity. Accordingly, (mt)CB1 receptors modulate the energy metabolism of several different cells (Benard et al., 2012; Dando et al., 2013;

**Table 1**  
Alterations in CB1 receptor expression in AD patients.

Disease stage	Brain Area analyzed	Technique	Finding	Reference
Clinically defined AD patients	Frontal cortex	WIN55-mediated <sup>35</sup> S-GTP $\gamma$ S binding  Western blot Western blot	Increased G-protein coupling.  Decreased CB1 receptor protein levels	Ramírez et al., 2005
Late stages	Cortical areas	<sup>3</sup> H-SR141716A autoradiography	No differences in CB1 receptor protein levels or availability	(Lee et al., 2010)
Braak III/IV and VI	Hippocampus	Western blot	No differences in CB1 receptor protein levels	(Mulder et al., 2011)
Braak I to Braak VI	Prefrontal cortex	<sup>125</sup> I-SD-7015 autoradiography	Increased CB1 receptor availability	(Farkas et al., 2012)
Braak V/VI	Frontal cortex	Western Blot	Decreased CB1 receptor protein levels	(Solas et al., 2013)
Mild to moderate	Cortex, insula, cingulum, striatum	PET + <sup>18</sup> F-MK-9740 radioligand	No difference in CB1 receptor availability  Increased G-protein coupling in the hilus of the dentate gyrus at early disease stages.	(Ahmad et al., 2014)
		WIN55-mediated <sup>35</sup> S-GTP $\gamma$ S binding	Decreased G-protein coupling in the lateral nucleus of the amygdala at early disease stages.	
Three disease groups grouped by disease progression	Frontal cortex, hippocampus, Entorhinal cortex, amygdala, basal forebrain, striatum	<sup>3</sup> H-CP55,940 autoradiography	Decreased G-protein coupling in different hippocampal areas at later disease stages. Increased CB1 receptor availability in Striatum and Pyramidal Subiculum at early stages  Increased CB1 receptor availability stages in the frontal cortex at mid diseases  Decreased CB1 receptor availability in Hippocampus at late disease stages.	(Manuel et al., 2014)

**Table 2**  
Alterations in CB1 receptor expression in animal models of AD.

Mouse model	Brain Area analyzed	Technique	Finding	Reference
APPswe/PS1 $\Delta$ E9, symptomatic	Hippocampal areas	Immunohistochemistry	Decreased neuronal CB1 protein levels Increased CB1 receptor mRNA level in prefrontal cortex, dorsal hippocampus and basolateral amygdala	(Kalifa et al., 2011)
3xTg-AD, symptomatic	Prefrontal cortex, prelimbic cortex, dorsal and ventral hippocampus, basolateral amygdala,	In situ hybridization	Decreased CB1 receptor mRNA levels in ventral Hippocampus	(Bedse et al., 2014)
3xTg-AD	Multiple brain regions	Immunostaining, immunofluorescence WIN55-mediated <sup>35</sup> S-GTP $\gamma$ S binding Western blot,	Decreased CB1 receptor protein levels in dorsal Hippocampus and Basolateral Amygdala Decreased G-protein coupling in Posterior Amygdala and Cortical layer VI	(González de San et al., 2021)
Tg2576 mice, presymptomatic	Hippocampus	Electrophysiological recordings	No differences in CB1 receptor protein level but altered membrane localization and function	(Maccarrone et al., 2018)
APP/PS1–21	Multiple brain regions	PET + <sup>18</sup> F-FMPEP-d2 radioligand, Western blotting	Decreased CB1 receptor availability in multiple regions. No differences in CB1 receptor protein in multiple areas analyzed.	(Takkinen et al., 2018)
5xFAD, symptomatic	Hippocampus	Western Blot	Decreased CB1 receptor protein levels Decreased CB1 receptor mRNA levels in Prefrontal Cortex and Hippocampus in male mice.	(Medina-Vera et al., 2020)
APP/PS1, presymptomatic	Multiple brain regions	Quantitative Real-Time PCR	Increased CB1 receptor mRNA levels in hypothalamus of male mice Increased CB1 receptor mRNA levels olfactory bulb, prefrontal cortex and hypothalamus of female mice	(Vidal-Palencia et al., 2022)

Hebert-Chatelain et al., 2014; Oláh et al., 2020; Pagano Zottola et al., 2022), and in particular, their persistent activation reduces both mitochondrial and glycolytic activity of astrocytes (Jimenez-Blasco et al., 2020). Currently, it is not known if the AD neuropathology alters mtCB1 receptors signaling in astrocytes. Similarly, further studies will be necessary to determine if astroglial CB1 receptors participate in the effects of cannabinoids in AD. Importantly, the outcome of astrocytic (mt)CB1 activation might also vary depending on multiple factors, such as disease progression, symptomatology severity or differences across individuals. Noteworthy, other functions that are altered in AD astrocytes, such as glutamate uptake, Ca<sup>2+</sup> homeostasis or cholesterol synthesis (Lee et al., 2022), will be interesting to explore in relation with the activity of CB1 receptors.

### 3. PD and ECS: a complex and incomplete picture

PD is the second most common neurodegenerative disorder, characterized by bradykinesia, loss of motor control and non-motor symptoms (e.g., cognitive decline, mood disorders, and others). The main neuropathologic hallmark of PD are the loss of dopaminergic neurons in the substantia nigra and a widespread accumulation of  $\alpha$ -synuclein in different brain areas (Parkinson, 2002; Poewe et al., 2017). Currently, the underpinnings that explain the development and progression of this debilitating disorder are scanty known. Interestingly, energy metabolism deficits have been proposed to participate in the development and/or progression of PD (Poewe et al., 2017). Despite the availability of effective therapies to reduce symptom progression, none of the current strategies promotes PD full remission (Poewe et al., 2017). Unfortunately, the chronic use of levodopa, the most effective anti-parkinsonism drug, causes dyskinesia and dystonia (Thanvi and Lo, 2004). This issue fueled the search for therapeutic targets capable of curing the disease,

with minimum side effects. In this context, the CB1 receptors activity have been explored in PD, as the substantia nigra is one of the brain areas in which the CB1 receptors are highly expressed (Kano et al., 2009). Moreover, exposure to THC alters motor activity (Stella, 2023), which might suggest that targeting the ECS system can alleviate the PD motor symptoms or the levodopa side effects. In this rationale, exposure to THC or its related synthetic analog nabilone, reduce the dyskinesia induced by chronic levodopa therapy in PD patients (Sieradzan et al., 2001), thus suggesting that the ECS might be a therapeutic target for motor symptoms correction in PD and during chronic antiparkinsonian medication. However, the ECS involvement in PD pathogenesis and development is complex.

The quantification of CB1 receptor levels in PD patients and rodent models resulted in a complex pattern. The mRNA levels of CB1 receptors are decreased in PD patients post mortem samples, specifically in the caudate nucleus, anterior dorsal putamen and external segment of the globus pallidus (Hurley et al., 2003). Similarly, CB1 receptor mRNA levels are reduced in the striatum of rats with parkinsonism-like symptoms induced by reserpine, a blocker of the vesicular monoamine transporters (Silverdale et al., 2001). Conversely, a time-dependent change in CB1 receptor mRNA levels was observed in mice carrying the deletion of either PARK1, PARK2 and PARK6 genes (García-Areñcibia et al., 2009), which are associated to hereditary PD pathogenesis in humans (Poewe et al., 2017). In particular, the levels of CB1 transcript in the caudate-putamen were decreased in the early phases of the disease, while increased at later stages (García-Areñcibia et al., 2009) in all mouse models studied. On the other hand, in vivo determination of CB1 receptor availability in PD patients, as measured by PET and the radioligand [<sup>18</sup>F] MK-9470, showed altered CB1 receptor availability in a region specific manner, with increased availability in nigrostriatal, mesolimbic, and mesocortical dopaminergic projection areas, while

decreased availability was found in the substantia nigra (Van Laere et al., 2012). In rats, the injection of the neurotoxic compound 6-hydroxydopamine (6-OHDA) results in the loss of dopaminergic and noradrenergic neurons, thus producing a PD-like rat model (Simola et al., 2007). The injection of 6-OHDA in the terminals (striatum) of the nigrostriatal pathway decreased CB1 receptor expression in the substantia nigra pars reticulata in rats (Walsh et al., 2010). Similarly, intrastriatal injection of 6-OHDA in rats resulted in decreased expression of CB1 receptors in internal globus pallidus and substantia nigra pars reticulata (Chaves-Kirsten et al., 2013). Conversely, intracerebroventricular injection of 6-OHDA result in increased CB1 receptors levels in the substantia nigra as measured by autoradiography in rat brain slices (González et al., 2006). These contradictory finding between PD patients and rodent models (summarized in Tables 3 and 4) can be ascribed to the poor capacity of rodent models to mimic the complex human PD neuropathology, but also is important to note that divergences might be explained by the different approaches used to induce 6-OHDA lesions (i.e., different injection sites), thus it is not clear if the result observed in rats are due differences in the spatial and temporal development of the lesions and appearance of PD-like symptoms in rats. Worthy of note, D2 dopamine receptors (D2R) form heterodimers with CB1 receptors (Kearn et al., 2005; Khan and Lee, 2014), a phenomenon that alters the signaling properties of both receptors (Bagher et al., 2016, 2017). In particular, whereas activation of each receptor alone activates a  $G_i$  signaling, the simultaneous activation of both CB1 and D2 receptors triggers a  $G_s$  signaling (Bagher et al., 2016, 2017). Furthermore, CB1 and D2 receptors also control the expression of each other (Blume et al., 2013). Thus, potential alterations in CB1 receptor expression might not only alter the ECS signaling in a region-specific manner in PD, but also it might modify the D2R-dependent signaling and impact PD pathology, a complex possibility that warrant further studies to fully elucidate the (patho)physiological role of this CB1 and DR2 heterodimerization.

Intriguingly, the levels of AEA are elevated in PD patients (Pisani et al., 2005, 2010). Similarly, the AEA levels in the Striatum are increased in the reserpine rat models (Gubellini et al., 2002), while the levels of 2-AG in the Globus Pallidus are elevated in the 6-OHDA rat model (Di Marzo et al., 2000). The induction of PD-like symptoms in non-human primates with the toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) resulted in region-specific changes, with increased 2-AG and AEA levels in the striatum, while only 2-AG levels were found to be increased in the substantia nigra (van der Stelt et al., 2005). Whether these eCB changes are part of PD neuropathology or just a secondary effect of the pharmacological lesions remains to be elucidated. In this context, the exogenous application of 2-AG, or its indirect increase via pharmacological inhibition of its degradation, protects mouse neurons from the neurodegenerative insult induced by systemic neurotoxin MPTP delivery (Fernández-Suárez et al., 2014; Mounsey et al., 2015). Nevertheless, further studies will be necessary to understand the exact nature of such eCBs changes observed in PD patients and animal models.

Overall, the involvement of ECS signaling in PD is very likely, but its mechanisms and consequences are not clear. The study of ECS

components, specifically the CB1 receptors and eCBs enzymatic machinery, in different brain cell types such as neurons, astrocytes and microglia might help to disentangle the conflictive results observed so far. Furthermore, the subcellular compartmentalization of CB1 receptor signaling warrant an special focus, as this particular characteristic enable the multimodal control of behavior via independent pools of this receptor (plasma membrane and mitochondria) in the striatonigral circuit (Soria-Gomez et al., 2021). In this context, mitochondrial dysfunction is proposed to be a key determinant of PD pathogenesis (Poewe et al., 2017), thus mtCB1 receptors signaling and its control of mitochondrial function become an interesting area to be explore in PD. The engagement of mtCB1 receptors inhibits mitochondrial function and negatively impact on brain bioenergetics (Benard et al., 2012; Hebert-Chatelain et al., 2014; Jimenez-Blasco et al., 2020), thus it might be possible that aberrant mtCB1 signaling participates in the mitochondrial dysfunction observed in PD. Further studies will be necessary to explore this intriguing possibility.

#### 4. Impaired CB1 receptor signaling in HD neuropathology

HD is a neurodegenerative disorder, which, in contrast to AD and PD (Knopman et al., 2021; Poewe et al., 2017), is caused by specific genetic alterations. Indeed, HD is the result of autosomal dominant mutation of the huntingtin gene (*HTT*) with the emergence of aberrant CAG trinucleotide repeats, that are variable in length (Bates, 2005; Bates et al., 2015). This results in the expression of a mutant huntingtin protein containing several long polyglutamine repeats, thus creating a neurotoxic protein prone to fragmentation and accumulation, which induces synaptic dysfunctions. Ultimately, the neuronal malfunction leads to motor dysfunction, cognitive impairment, neuropsychiatric symptoms (e.g., obsessive compulsive behavior, apathy) and ultimately death (Bates et al., 2015). Currently, most of the HD therapies are palliative and target the motor dysfunctions (Vasincu et al., 2022), without addressing the pathology itself.

Despite being HD a disorder that affect the whole brain structure, the striatum is particularly sensitive to the neurotoxic damage induced by mutant huntingtin, which is reflected in the striatal atrophy observed in HD patients (Bates et al., 2015). In the striatum, CB1 receptors are densely expressed in dopaminergic medium spiny neurons and control motor behaviors (Martín et al., 2008). Thus, an ECS malfunction might be involved in the HD development and progression. In this context, the level of eCB has been measured in HD mouse models R6/2 and R6/1 which express the exon 1 of human huntingtin gene (Li et al., 2005), but the resulting data is conflicting. Whereas 2-AG levels were reported to be decreased in the cortex in presymptomatic R6/2 HD mice (Bisogno et al., 2008), other group using the R6/1 mice model found that 2-AG level were increased in the cortex, with a parallel decrease in the AEA levels in the hippocampus (Dowie et al., 2009). In the symptomatic R6/2 mice, 2-AG levels were reduced both in the striatum and cortex, while AEA was reduced in the striatum but increased in the cortex (Bisogno et al., 2008). Conversely, whole brain 2-AG levels were found to be increased in the R6/2 mice (Bari et al., 2013) (Table 6). This conflictive results might be explained by differences in symptom progression in the R6/2

**Table 3**  
Alterations in eCBs level, CB1 receptor expression in PD patients.

Disease stage	Sample analyzed	Technique	Finding	Reference
Late stage	Caudate nucleus, anterior dorsal putamen, external segment of globus pallidus	Reverse transcription polymerase chain reaction (RT-PCR)	Decreased levels of CB1 receptors mRNA	Hurley et al., 2003
Mix of early, medium and late stages	Substantia nigra and dopaminergic projection areas	PET + $^{18}\text{F}$ -MK-9470 radioligand and MRI	Increased CB1 receptor availability in nigrostriatal, mesolimbic, and mesocortical dopaminergic projection areas, while decreased availability in the substantia nigra	Van Laere et al., 2012
Mix of early, medium and late stages	Cerebrospinal fluid	Liquid chromatography (LC) with fluorimetric detection	Increased levels of AEA, independent of disease stage, but higher levels were observed on patients without treatment	Pisani et al., 2005, 2010

**Table 4**  
Alterations in eCBs level, CB1 receptor expression in animal models of PD.

Rodent model	Brain area analyzed	Technique	Finding	Reference
Rats treated with reserpine	Striatum	In situ hybridization	Decreased levels of CB1 receptors mRNA	Silverdale et al., 2001
Rats treated with reserpine	Basal ganglia	Isotope dilution Gas chromatography-Mass Spectroscopy (GC-MS)	Increased levels of 2-AG in the Globus Pallidus	Di Marzo et al., 2000;
Rats injected with 6-OHDA on nigrostriatal pathway terminals	Substantia nigra	Immunohistochemistry	Decreased CB1 receptor protein in Substantia nigra pars reticulata	Walsh et al., 2010
Rats injected with 6-OHDA, intrastriatal	Basal ganglia	Immunohistochemistry	Decreased CB1 receptor protein in the internal Globus Pallidus and Substantia Nigra Pars Reticulata.	Chaves-Kirsten et al., 2013
Rats injected with 6-OHDA, Intra-cerebroventricular	Basal ganglia	Western blot	Increased CB1 receptor level in substantia nigra	González et al., 2006
Rats injected with 6-OHDA, on Substantia Nigra	Striatum	GC-MS	Increased levels of AEA in the Striatum	Gubellini et al., 2002
PARK1, PARK2 and PARK6 KO mice	Caudate-putamen	????	Time dependent changes in CB1 receptors mRNA level: decreased at early disease stages, while increased in later disease stages	García-Arencibia et al., 2009
Marmosets treated with MPTP	Basal ganglia	Isotope dilution atmospheric pressure chemical ionization LC- MS (LC-APCI-MS)	Increased levels of 2-AG in Striatum, Substantia Nigra. Increased levels of AEA on Striatum	van der Stelt et al., 2005

and R6/1 mice models and their different efficiency in transgene expression, whose is higher level in R6/2 mice (75%) than R6/1 mice (31%) (Li et al., 2005). Alternatively, the results might be explained also by differences in sample extraction and processing. This inconclusive eCBs data might cast doubt about the potential role of the ECS in HD neuropathology, however the study of CB1 receptors expression has been more consistent. The in vivo determination of CB1 receptor availability with PET and a specific radioligand, have shown an extensive decrease in brain CB1 receptors in early symptomatic HD patients (Ceccarini et al., 2019; Glass et al., 2000; Laere et al., 2010), with a further level decay in intermediate HD (Glass et al., 2000). The analysis of post mortem samples from HD patients has also shown a decrease in the CB1 receptor availability (Glass et al., 1993) (Table 5). Similarly, specific sections of the basal ganglia in HD genetic mouse models present a reduction in CB1 receptor mRNA levels (Denovan-Wright and Robertson, 2000; Dowie et al., 2009; Lastres-Becker et al., 2002), protein levels (Dowie et al., 2009), G-protein coupling (Lastres-Becker et al., 2002) and CB1 receptor availability (Dowie et al., 2009; Lastres-Becker et al., 2002; Ooms et al., 2014) (see Table 6 for details). Similar results have been observed in rodent treated with 3-nitropropionic acid (3-NP) (Lastres-Becker et al., 2004), a neurotoxin that inhibits mitochondrial complex II activity and cause a specific striatal degeneration and HD-like symptoms (Brouillet, 2014; Túnez et al., 2010). Specifically, rats treated with 3-NP presented a reduction in CB1 receptor G-protein coupling before the onset of HD-like symptoms, but without changes in mRNA levels. However, upon striatal degeneration, a marked reduction in both the G-protein coupling and mRNA levels was observed (Lastres-Becker et al., 2004). Interestingly, in vitro analysis using immortalized striatal neuroblasts suggest that mutant huntingtin downregulate CB1 receptor expression via repressor element 1 silencing transcription factor (REST) (Blázquez et al., 2011), thus suggesting that CB1 receptors reduction is

part of the mechanisms of HD neuropathology. In this rationale, CB1 receptor deletion in R6/2 HD mouse model aggravates the symptomatology (Blázquez et al., 2011), and similar results were observed for CB1 deletion in the N171-82Q mouse model (Mievis et al., 2011), which expresses the N-terminally truncated human huntingtin cDNA. Noteworthy, specific deletion of CB1 receptors in glutamatergic corticostriatal terminals worsen the striatal neurodegeneration in the R2/6 HD mouse model (Chiarlone et al., 2014), indicating that this cellular pool of CB1 receptors participates in the progression of HD neuropathology. This observation underlines the neuroprotective role exerted by CB1 receptors, whose activity minimizes the excitotoxic damage induced by the neurotoxin quinolinate in vivo (Chiarlone et al., 2014). Importantly, widespread excitotoxic damage induced by glutamate and aberrant NMDAR function is observed during HD (Kaplan and Stockwell, 2012), suggesting that the loss of CB1 receptors in glutamatergic corticostriatal terminals might increase the susceptibility to excitotoxic damage during HD progression. Overall, these results suggest that the ECS signaling is altered in HD, especially at the level of CB1 receptors.

Thus, could the stimulation of CB1 receptors improve HD symptomatology? This idea has been explored using exogenous cannabinoids both in animal models and humans. In the R6/2 HD mouse model, THC exposure causes a reduction of HD-like symptomatology (Blázquez et al., 2011). In clinical trials, mixed results have been observed with Nabiximol (a mix of THC + cannabidiol (CBD) at ~1:1 ratio). Whereas in a first clinical trial this cannabinoid mix did not improve patients motor symptoms (López-Sendón Moreno et al., 2016), a following clinical trial showed that Nabiximol treatment improves patients motor symptoms, specially dystonia (Saft et al., 2018). Of note the presence of CBD in Nabiximol make difficult to determine if the main effect of this drug is due solely to THC, and potentially, CB1 receptor engagement, as it is suggested that CBD antagonizes CB1 receptors and that CBD can bind to

**Table 5**  
Alterations in eCBs level, CB1 receptor expression in HD patients.

Disease stage	Brain area analyzed	Technique	Finding	Reference
Presymptomatic	Whole brain	PET + <sup>18</sup> F-MK-9470 radioligand	Decrease CB1 receptors availability in prefrontal cortex	Ceccarini et al., 2019
Shoulson–Fahn stage I (early symptomatic)	Whole brain	PET + <sup>18</sup> F-MK-9470 radioligand and MRI	Decrease CB1 receptor availability in the gray matter of the cerebrum, cerebellum, and brain stem	Laere et al., 2010
HD grade 0 to 3 (presymptomatic, intermediate, advanced)	Multiple brain regions	<sup>3</sup> H-CP55,940 autoradiography	Decreased CB1 receptor availability in Caudate Nucleus, Putamen and Globus Pallidus across all grades. Decrease magnitude correlated with grade severity	Glass et al., 2000
HD grade 1 and 3	Substantia Nigra	<sup>3</sup> H-CP55,940 autoradiography	Decrease CB1 receptors availability in Substantia Nigra Pars Reticulata	Glass et al., 1993



**Table 6**  
Alterations in eCBs level, CB1 receptor expression in animal models of HD.

Rodent model	Brain area analyzed	Technique	Finding	Reference
R6/1 mouse, presymptomatic	Cortex and Hippocampus	LC-MS	Increased 2-AG levels in the Cortex, while decreased AEA levels in the Hippocampus	Dowie et al., 2009
R6/2 mouse, presymptomatic	Whole brain	LC-MS	Increased 2-AG levels	Bari et al., 2013
R6/2 mouse, presymptomatic	Cortex	LC-APCI-MS	Decreased 2-AG levels	Bisogno et al., 2008
R6/2 mouse, symptomatic	Striatum, Cortex and Hippocampus	LC-APCI-MS	Decreased 2-AG levels in Striatum and Cortex. Reduced AEA levels in the Hippocampus, but increased in the Cortex	Bisogno et al., 2008
R6/2 mouse, presymptomatic	Striatum, Cortex and Hippocampus	In situ hybridization  Northern blot Immunohistochemistry	Decreased CB1 receptor mRNA levels in lateral Striatum, and in some neurons in Cortex and Hippocampus	Denovan-Wright and Robertson, 2000
R6/1 mouse	Basal Ganglia	In situ hybridization  <sup>3</sup> H-CP55,940 autoradiography	Decreased CB1 receptor mRNA levels in the striatum. Decreased CB1 receptor protein level in Substantia Nigra Decreased CB1 receptor availability in all Basal Ganglia	Dowie et al., 2009
R6/2 mouse, Presymptomatic and symptomatic	Whole brain	PET + <sup>18</sup> F-MK-9470 radioligand  In situ hybridization	Decreased CB1 receptor availability in caudate-putamen and globus pallidus in all stages. Further decrease on hippocampus, caudate-putamen, superior colliculus, thalamic nucleus and cerebellum in symptomatic stages	Ooms et al., 2014
HD97 inducible mouse	Basal ganglia	<sup>3</sup> H-CP55,940 autoradiography  WIN55-mediated <sup>35</sup> S-GTPγS binding	Decreased CB1 receptor mRNA levels in Caudate-Putamen. Decreased CB1 receptor availability in Caudate-Putamen, Globus Pallidus, entopeduncular nucleus and substantia nigra pars reticulata Decreased G-protein coupling in Globus Pallidus	Lastres-Becker et al., 2002
Rat treated with 3-NP	Multiple brain regions	WIN55-mediated <sup>35</sup> S-GTPγS binding  In situ hybridization	Reduction in CB1 receptor G-protein coupling before the striatal degeneration.  Reduction in CB1 receptors mRNA levels and G-protein coupling after striatal degeneration	Lastres-Becker et al., 2004

several molecular targets (Britch et al., 2021). Nevertheless, the THC-related compound nabilone has been shown to promote a small improvement in motor symptoms of patients (Curtis et al., 2009). Despite the need of further studies to disentangle the potential role of THC and CBD in alleviating HD pathology, it could be suggested that Nabiximol effect on motor function can be explained by THC itself. Overall, the impact of exogenous cannabinoids on symptomatic HD is mild. This could be explained by the progressive loss of the CB1 receptors in HD and concomitant loss in the total signaling capacity, in other words, there are not enough CB1 receptors to trigger a neuroprotective role in later stages of HD symptomatology. Thus, it will be interesting to test the impact of CB1 receptor agonists in pre symptomatic HD and determine if this approach slows down HD progression.

Recently, it has been shown that astrocytes dysfunction in HD might be secondary to the neuronal impairment induced by mutant huntingtin in R6/2 mice (Gangwani et al., 2023), in other words, astrocytes are not the main root of HD neuropathology. Nevertheless, it has been shown that astrocytes do accumulate mutant huntingtin and participate in HD progression (Lee et al., 2022; Palpagama et al., 2019). Astrocyte Ca<sup>2+</sup> dynamics (i.e., calcium rises amplitude, area and frequency) are reduced in the R6/2 mice, impairing striatal tonic GABA release and promoting obsessive compulsive-like behaviors (Yu et al., 2018). In a following study, the same group showed that activation of G<sub>i</sub> signaling in astrocytes via a DREADD strategy, which result in astrocytes Ca<sup>2+</sup> elevations (Durkee et al., 2019), is able to correct the deficient Ca<sup>2+</sup> dynamics in R6/2 mice and improve their phenotype (Yu et al., 2020). In this context, CB1 receptors engagement increase both intracellular and mitochondrial Ca<sup>2+</sup> in astrocytes (Eraso-Pichot et al., 2023; Serrat et al., 2021), thus as CB1 receptors levels are reduced in HD, it is plausible that decreased astroglial CB1 receptors signaling in HD might participate in the altered Ca<sup>2+</sup> dynamics observed in the R2/6 HD mice (Yu et al., 2018, 2020).

Similar to AD, pre symptomatic brain glucose hypometabolism is a hallmark of HD (Antonini et al., 1996; Grafton et al., 1992; Kuwert et al., 1993), and also its cellular and molecular origin(s) are unknown. Interestingly, HD symptomatology can be alleviated by dietary anaplerotic therapy using triheptanoin (Adanyeguh et al., 2015). This triglyceride composed by three fatty acid of seven-carbon length is able to promote the replenishment of TCA intermediates, a key metabolic process that is carried out exclusively by astrocytes in the brain (Schousboe et al., 2019; Weber and Barros, 2015). Thus, it is plausible that triheptanoin is consumed specifically by astrocytes, which might cause a reduction in the amount of glucose consumed for replenishment of TCA intermediates. This might result in a glucose sparing phenomenon, in which the consumption of alternatives fuels by astrocytes might secure neurons glucose accessibility in the face of scarce brain glucose levels as observed in HD (Polyzos et al., 2019). Interestingly, this glucose sparing hypothesis have been also proposed for the beneficial effects of ketogenic diet on brain function (Valdebenito et al., 2016). The involvement of astrocytes in HD metabolic failure have been proposed to result from the reprogramming of astrocyte mitochondrial function toward lipid oxidation and concomitant increase in ROS production in the HdhQ (150/150) mouse model (Polyzos et al., 2019), which carries a longer CAG repetition of the exon 1 of human huntingtin when compared to other HD mouse models (Lin et al., 2001). Noteworthy, healthy astrocyte are able to metabolize lipids (Eraso-Pichot et al., 2018) and the loss of this capacity induce neuroinflammation and neurodegeneration (Mi et al., 2023). This contradictory data might be explained by the fatty acid accumulation and reduced availability of glucose in the striatum (Polyzos et al., 2019), which force astrocytes to rely heavily in lipid oxidation to sustain their own energy needs, at the expense of increasing ROS production. Alternatively, the ROS increase may not be due increased lipid oxidation but rather explained by impaired antioxidant capacity due a reduction in the ascorbic acid shuttle between astrocytes

and neurons in HD mouse models (Acuña et al., 2013; Boussicault et al., 2014; Lee et al., 2022). In this context, activation of CB1 receptors in astrocyte mitochondria reduce complex I activity and ROS production (Jimenez-Blasco et al., 2020), thus the effect of cannabinoids on HD symptomatology might potentially be related to the reduction of ROS production by astrocyte mitochondria. On this rationale, 3-NP neurotoxic effects result from inhibition of mitochondrial complex II and concomitant increase in ROS production (Túnez et al., 2010). Interestingly, administration of the synthetic cannabinoid WIN55,212-2 before 3-NP treatment protects rats from the deleterious effect of the neurotoxin (Maya-López et al., 2017). Consistent with this observation, deletion of CB1 receptors worsens the neurotoxic effect of 3-NP in mice (Mievis et al., 2011). In parallel to this putative reduction in ROS production induced by CB1 receptor activation, a reduction of astroglial glucose consumption induced by cannabinoids (Jimenez-Blasco et al., 2020), might spare enough glucose for neurons to increase their antioxidant capacity via pentose phosphate pathway (Bolaños and Almeida, 2010), thus potentially allowing neurons to better survive the oxidative stress that occurs during HD (Kumar and Ratan, 2016). Indeed, reducing the ROS levels caused by lipid oxidation using an electron scavenger, protect neurons from oxidative damage and improve motor symptoms in HD mice (Polyzos et al., 2019). Nevertheless, is important to note that the cannabinoid-mediated reduction of glucose metabolism reduces brain lactate availability and impact brain function (Jimenez-Blasco et al., 2020), thus the role of lactate in HD warrant a further description to understand if a reduction in lactate levels might be beneficial or noxious in the altered HD bioenergetics settings.

In summary, there is compelling evidence for reduced CB1 receptor signaling in HD. However, a better understanding of the cellular and molecular components involved of such deficit requires further attention. Noteworthy, deficits in CB1 receptor signaling in astrocytes might partially explain the beneficial effects of cannabinoids on HD.

## 5. Conclusion and future perspectives

The main brain ECS signaling hub, the CB1 receptors, are prominently expressed across the entire brain parenchyma and exert a powerful control of brain function and behavior. Thus, it is not surprising that this signaling system might be altered in pathological conditions. Indeed, several research lines on AD, PD and HD have found data consistent with aberrant ECS signaling in these neurodegenerative disorders. However, this knowledge had started to become narrow, as the field of brain ECS is evolving quickly, with new cellular and molecular substrates joining the complex array of intracellular and intercellular signaling triggered by CB1 receptors engagement. For instance, several studies were performed before the demonstration of functional expression of CB1 receptors in astrocytes and other glia cells. Moreover, the existence of mitochondrial associated CB1 receptors has radically changed the understanding about CB1 receptor signaling. In this rationale, the emerging concept of independent subcellular pools of CB1 receptor (Soria-Gomez et al., 2021) is an important aspect to be considered in future studies. Importantly, aging is considered the main risk factor for several neurodegenerative disorders (Hou et al., 2019), and surprisingly, we do not fully understand how the ECS evolve during aging. Indeed, just a handful of studies have looked into how aging shape the ECS signaling, but current data indicates that older people respond differently to exogenous cannabinoids (Bilkei-Gorzo et al., 2017; Mueller et al., 2021). Thus, it is recommended to apply with care the current knowledge about the ECS in young adulthood into the neurodegenerative disorders research, especially in AD and PD in which aging is a strong risk factor. In conclusion, the involvement of ECS and signaling warrant new interdisciplinary approaches to take into account the new discoveries about CB1 receptors expression in diverse brain cells and its direct control of mitochondrial function.

## Authors contribution

I-F-M., A.E-P. and G.M. contributed to the conceptualization and writing of the review. T.D.T and B.F.M. contributed by data curation and writing. All authors read and approved the manuscript version.

## Declaration of Competing Interest

The authors declare that there are no competing interests associated with the manuscript.

## Data availability

No data was used for the research described in the article.

## Acknowledgements

We thank all the current and past members of Marsicano lab for their helpful discussions and invaluable support. This study was funded by INSERM (to G.M.); the European Research Council (Micabra, ERC-2017-AdG-786467, ERC-2014-PoC-640923, ERC-2010-StG-260515 to G.M.); Fondation pour la Recherche Medicale (DRM20101220445, to G.M and SPF201909009268 to AE-P); EMBO Long-term Fellowship ALTF87-2018 (to IF-M); the Human Frontiers Science Program (to G.M.); Region Aquitaine (CanBrain, AAP2022A-2021-16763610 and -17219710 to G. M.); French State/Agence Nationale de la Recherche (CaCoVi, ANR 18-CE16-0001-02; MitObesity, ANR 18-CE14-0029-01; ERA-Net Neuron CanShank, ANR-21-NEU2-0001-04, to G.M) (ANR-19-CE14-0039 to L. B.); University of Bordeaux's IdEx "Investments for the Future" program / GPR BRAIN\_2030.

## References

- 2023 Alzheimer's disease facts and figures, 2023. Alzheimer's & Dementia n/a. <https://doi.org/10.1002/alz.13016> n.d.
- Abate, G., Uberti, D., Tambaro, S., 2021. Potential and limits of cannabinoids in Alzheimer's disease therapy. *Biology (Basel)* 10, 542. <https://doi.org/10.3390/biology10060542>.
- Acuña, A.I., Esparza, M., Kramm, C., Beltrán, F.A., Parra, A.V., Cepeda, C., Toro, C.A., Vidal, R.L., Hetz, C., Concha, I.I., Brauchi, S., Levine, M.S., Castro, M.A., 2013. A failure in energy metabolism and antioxidant uptake precede symptoms of Huntington's disease in mice. *Nat. Commun.* 4, 2917. <https://doi.org/10.1038/ncomms3917>.
- Adanyeguh, I.M., Rinaldi, D., Henry, P.-G., Caillet, S., Valabregue, R., Durr, A., Mochel, F., 2015. Triheptanoin improves brain energy metabolism in patients with Huntington disease. *Neurology* 84, 490–495. <https://doi.org/10.1212/WNL.0000000000001214>.
- Agarwal, S., Yadav, A., Chaturvedi, R.K., 2017. Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders. *Biochem. Biophys. Res. Commun.* 483, 1166–1177. <https://doi.org/10.1016/j.bbrc.2016.08.043>.
- Ahmad, R., Goffin, K., Van den Stock, J., De Winter, F.-L., Cleeren, E., Bormans, G., Tournoy, J., Persoons, P., Van Laere, K., Vandenberghe, M., 2014. In vivo type 1 cannabinoid receptor availability in Alzheimer's disease. *Eur. Neuropsychopharmacol.* 24, 242–250. <https://doi.org/10.1016/j.euroneuro.2013.10.002>.
- Alger, B.E., 2002. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. *Prog. Neurobiol.* 68, 247–286. [https://doi.org/10.1016/S0304-0082\(02\)00080-1](https://doi.org/10.1016/S0304-0082(02)00080-1).
- Antonini, A., Leenders, K.L., Spiegel, R., Meier, D., Vontobel, P., Weigell-Weber, M., Sanchez-Pernaute, R., de Yébenes, J.G., Boesiger, P., Weindl, A., Maguire, R.P., 1996. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. *Brain* 119 (Pt 6), 2085–2095. <https://doi.org/10.1093/brain/119.6.2085>.
- Araque, A., Castillo, P.E., Manzoni, O.J., Tonini, R., 2017. Synaptic functions of endocannabinoid signaling in health and disease. *Neuropharmacology* 124, 13–24. <https://doi.org/10.1016/j.neuropharm.2017.06.017>.
- Asher, S., Priefer, R., 2022. Alzheimer's disease failed clinical trials. *Life Sci.* 306, 120861 <https://doi.org/10.1016/j.lfs.2022.120861>.
- Aso, E., Ferrer, I., 2014. Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic. *Front. Pharmacol.* 5, 37. <https://doi.org/10.3389/fphar.2014.00037>.
- Aso, E., Palomer, E., Juvés, S., Maldonado, R., Muñoz, F.J., Ferrer, I., 2012. CB1 agonist ACEA protects neurons and reduces the cognitive impairment of AβPP/PS1 mice. *J. Alzheimers Dis.* 30, 439–459. <https://doi.org/10.3233/JAD-2012-111862>.

- Aso, E., Sánchez-Pla, A., Vegas-Lozano, E., Maldonado, R., Ferrer, I., 2015. Cannabis-based medicine reduces multiple pathological processes in A $\beta$ PP/PS1 mice. *J. Alzheimers Dis.* 43, 977–991. <https://doi.org/10.3233/JAD-141014>.
- Aso, E., Andrés-Benito, P., Ferrer, I., 2016. Delineating the efficacy of a cannabis-based medicine at advanced stages of dementia in a murine model. *J. Alzheimers Dis.* 54, 903–912. <https://doi.org/10.3233/JAD-160533>.
- Aso, E., Andrés-Benito, P., Ferrer, I., 2018. Genetic deletion of CB1 cannabinoid receptors exacerbates the Alzheimer-like symptoms in a transgenic animal model. *Biochem. Pharmacol.* 157, 210–216. <https://doi.org/10.1016/j.bcp.2018.08.007>.
- Bagher, A.M., Laprairie, R.B., Kelly, M.E.M., Donovan-Wright, E.M., 2016. Antagonism of dopamine receptor 2 long affects cannabinoid receptor 1 signaling in a cell culture model of striatal medium spiny projection neurons. *Mol. Pharmacol.* 89, 652–666. <https://doi.org/10.1124/mol.116.103465>.
- Bagher, A.M., Laprairie, R.B., Toguri, J.T., Kelly, M.E.M., Donovan-Wright, E.M., 2017. Bidirectional allosteric interactions between cannabinoid receptor 1 (CB1) and dopamine receptor 2 long (D2L) heterotetramers. *Eur. J. Pharmacol.* 813, 66–83. <https://doi.org/10.1016/j.ejphar.2017.07.034>.
- Baker, D., Pryce, G., Giovannoni, G., Thompson, A.J., 2003. The therapeutic potential of cannabis. *Lancet Neurol.* 2, 291–298. [https://doi.org/10.1016/s1474-4422\(03\)00381-8](https://doi.org/10.1016/s1474-4422(03)00381-8).
- Bari, M., Battista, N., Valenza, M., Mastrangelo, N., Malaponti, M., Catanzaro, G., Centonze, D., Finazzi-Agrò, A., Cattaneo, E., Maccarrone, M., 2013. In vitro and in vivo models of Huntington's disease show alterations in the endocannabinoid system. *FEBS J.* 280, 3376–3388. <https://doi.org/10.1111/febs.12329>.
- Basavarajappa, B.S., Shivakumar, M., Joshi, V., Subbanna, S., 2017. Endocannabinoid system in neurodegenerative disorders. *J. Neurochem.* 142, 624–648. <https://doi.org/10.1111/jnc.14098>.
- Bates, G.P., 2005. The molecular genetics of Huntington disease — a history. *Nat. Rev. Genet.* 6, 766–773. <https://doi.org/10.1038/nrg1686>.
- Bates, G.P., Dorsey, R., Gusella, J.F., Hayden, M.R., Kay, C., Leavitt, B.R., Nance, M., Ross, C.A., Scahill, R.I., Wetzel, R., Wild, E.J., Tabrizi, S.J., 2015. Huntington disease. *Nat. Rev. Dis. Primers* 1, 15005. <https://doi.org/10.1038/nrdp.2015.5>.
- Beard, E., Lengacher, S., Dias, S., Magistretti, P.J., Finsterwald, C., 2021. Astrocytes as key regulators of brain energy metabolism: new therapeutic perspectives. *Front. Physiol.* 12, 825816. <https://doi.org/10.3389/fphys.2021.825816>.
- Bedse, G., Romano, A., Cianci, S., Lavecchia, A.M., Lorenzo, P., Elphick, M.R., Laferla, F.M., Vendemiale, G., Grillo, C., Altieri, F., Cassano, T., Gaetani, S., 2014. Altered expression of the CB1 cannabinoid receptor in the triple transgenic mouse model of Alzheimer's disease. *J. Alzheimers Dis.* 40, 701–712. <https://doi.org/10.3233/JAD-131910>.
- Bélanger, M., Allaman, I., Magistretti, P.J., 2011. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. *Cell Metab.* 14, 724–738. <https://doi.org/10.1016/j.cmet.2011.08.016>.
- Benard, G., Massa, F., Puente, N., Lourenco, J., Bellocchio, L., Soria-Gomez, E., Matias, I., Delamarre, A., Metna-Laurent, M., Cannich, A., Hebert-Chatelain, E., Mulle, C., Ortega-Gutierrez, S., Martin-Pontecha, M., Klugmann, M., Guggenhuber, S., Lutz, B., Gertsch, J., Chaouloff, F., Lopez-Rodriguez, M.L., Grandes, P., Rossignol, R., Marsicano, G., 2012. Mitochondrial CB1 receptors regulate neuronal energy metabolism. *Nat. Neurosci.* 15, 558–564. <https://doi.org/10.1038/nn.3053>.
- Berry, A.J., Zubko, O., Reeves, S.J., Howard, R.J., 2020. Endocannabinoid system alterations in Alzheimer's disease: a systematic review of human studies. *Brain Res.* 1749, 147135. <https://doi.org/10.1016/j.brainres.2020.147135>.
- Bilkei-Gorzo, A., Albayram, O., Draffehn, A., Michel, K., Piyanova, A., Oppenheimer, H., Dvir-Ginzberg, M., Rácz, I., Ulas, T., Imbeault, S., Bab, I., Schultze, J.L., Zimmer, A., 2017. A chronic low dose of  $\Delta^9$ -tetrahydrocannabinol (THC) restores cognitive function in old mice. *Nat. Med.* 23, 782–787. <https://doi.org/10.1038/nm.4311>.
- Bisogno, T., Martire, A., Petrosino, S., Popoli, P., Di Marzo, V., 2008. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease. *Neurochem. Int.* 52, 307–313. <https://doi.org/10.1016/j.neuint.2007.06.031>.
- Blanton, H.L., Barnes, R.C., McHann, M.C., Bilbrey, J.A., Wilkerson, J.L., Guindon, J., 2021. Sex differences and the endocannabinoid system in pain. *Pharmacol. Biochem. Behav.* 202, 173107. <https://doi.org/10.1016/j.pbb.2021.173107>.
- Blázquez, C., Chiarlone, A., Sagredo, O., Aguado, T., Pazos, M.R., Resel, E., Palazuelos, J., Julien, B., Salazar, M., Börner, C., Benito, C., Carrasco, C., Diez-Zaera, M., Paoletti, P., Díaz-Hernández, M., Ruiz, C., Sendtner, M., Lucas, J.J., de Yébenes, J.G., Marsicano, G., Monory, K., Lutz, B., Romero, J., Alberch, J., Ginés, S., Kraus, J., Fernández-Ruiz, J., Galve-Roperh, I., Guzmán, M., 2011. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. *Brain* 134, 119–136. <https://doi.org/10.1093/brain/awq278>.
- Blume, L.C., Bass, C.E., Childers, S.R., Dalton, G.D., Roberts, D.C.S., Richardson, J.M., Xiao, R., Selley, D.E., Howlett, A.C., 2013. Striatal CB1 and D2 receptors regulate expression of each other, CRIP1A and  $\delta$  opioid systems. *J. Neurochem.* 124, 808–820. <https://doi.org/10.1111/jnc.12139>.
- Bolaños, J.P., Almeida, A., 2010. The pentose-phosphate pathway in neuronal survival against nitrosative stress. *IUBMB Life* 62, 14–18. <https://doi.org/10.1002/iub.280>.
- Bonini, S.A., Premoli, M., Tambaro, S., Kumar, A., Maccarinelli, G., Memo, M., Mastini, A., 2018. Cannabis sativa: a comprehensive ethnopharmacological review of a medicinal plant with a long history. *J. Ethnopharmacol.* 227, 300–315. <https://doi.org/10.1016/j.jep.2018.09.004>.
- Boussicault, L., Héraud, A.-S., Calingasan, N., Petit, F., Malignon, C., Merienne, N., Jan, C., Gaillard, M.-C., Lerchundi, R., Barros, L.F., Escartin, C., Delzescaux, T., Mariani, J., Hantraye, P., Beal, M.F., Brouillet, E., Véga, C., Bonvento, G., 2014. Impaired brain energy metabolism in the BACHD mouse model of Huntington's disease: critical role of astrocyte-neuron interactions. *J. Cereb. Blood Flow Metab.* 34, 1500–1510. <https://doi.org/10.1038/jcbfm.2014.110>.
- Britch, S.C., Babalonis, S., Walsh, S.L., 2021. Cannabidiol: pharmacology and therapeutic targets. *Psychopharmacology* 238, 9–28. <https://doi.org/10.1007/s00213-020-05712-8>.
- Brouillet, E., 2014. The 3-NP model of striatal neurodegeneration. *Curr. Protoc. Neurosci.* 67. <https://doi.org/10.1002/0471142301.ns0948s67>, 9.48.1–9.48.14.
- Busquets-García, A., Bains, J., Marsicano, G., 2018. CB1 receptor signaling in the brain: extracting specificity from ubiquity. *Neuropsychopharmacol.* 43, 4–20. <https://doi.org/10.1038/npp.2017.206>.
- Busquets-García, A., Bolaños, J.P., Marsicano, G., 2022. Metabolic messengers: endocannabinoids. *Nat. Metab.* 4, 848–855. <https://doi.org/10.1038/s42255-022-00600-1>.
- Calakos, K.C., Bhatt, S., Foster, D.W., Cosgrove, K.P., 2017. Mechanisms underlying sex differences in cannabis use. *Curr. Addict. Rep.* 4, 439–453. <https://doi.org/10.1007/s40429-017-0174-7>.
- Ceccarini, J., Ahmad, R., Van de Vliet, L., Casteels, C., Vandenbulcke, M., Vandenbergh, W., Van Laere, K., 2019. Behavioral symptoms in premanifest Huntington disease correlate with reduced frontal CB1R levels. *J. Nucl. Med.* 60, 115–121. <https://doi.org/10.2967/jnumed.118.210393>.
- Chaves-Kirsten, G.P., Mazucanti, C.H.Y., Real, C.C., Souza, B.M., Britto, L.R.G., Torráo, A.S., 2013. Temporal changes of CB1 cannabinoid receptor in the basal ganglia as a possible structure-specific plasticity process in 6-OHDA lesioned rats. *PLoS One* 8, e76874. <https://doi.org/10.1371/journal.pone.0076874>.
- Chen, R., Zhang, J., Wu, Y., Wang, D., Feng, G., Tang, Y.-P., Teng, Z., Chen, C., 2012. Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease. *Cell Rep.* 2, 1329–1339. <https://doi.org/10.1016/j.celrep.2012.09.030>.
- Chen, R., Zhang, J., Fan, N., Teng, Z.-Q., Wu, Y., Yang, H., Tang, Y.-P., Sun, H., Song, Y., Chen, C., 2013.  $\Delta^9$ -THC-induced synaptic and memory impairments are mediated through COX-2 signaling. *Cell* 155, 1154–1165. <https://doi.org/10.1016/j.cell.2013.10.042>.
- Chiarlone, A., Bellocchio, L., Blázquez, C., Resel, E., Soria-Gómez, E., Cannich, A., Ferrero, J.J., Sagredo, O., Benito, C., Romero, J., Sánchez-Prieto, J., Lutz, B., Fernández-Ruiz, J., Galve-Roperh, I., Guzmán, M., 2014. A restricted population of CB1 cannabinoid receptors with neuroprotective activity. *Proc. Natl. Acad. Sci.* 111, 8257–8262. <https://doi.org/10.1073/pnas.1400988111>.
- Cristino, L., Bisogno, T., Di Marzo, V., 2020. Cannabinoids and the expanded endocannabinoid system in neurological disorders. *Nat. Rev. Neurol.* 16, 9–29. <https://doi.org/10.1038/s41582-019-0284-z>.
- Curtis, A., Mitchell, I., Patel, S., Ives, N., Rickards, H., 2009. A pilot study using nabilone for symptomatic treatment in Huntington's disease. *Mov. Disord.* 24, 2254–2259. <https://doi.org/10.1002/mds.22809>.
- Dando, I., Donadelli, M., Costanzo, C., Dalla Pozza, E., D'Alessandro, A., Zolla, L., Palmieri, M., 2013. Cannabinoids inhibit energetic metabolism and induce AMPK-dependent autophagy in pancreatic cancer cells. *Cell Death Dis.* 4, e664. <https://doi.org/10.1038/cddis.2013.151>.
- De Meij, J., Alfaneq, Z., Morel, L., Decoeur, F., Leyrolle, Q., Picard, K., Carrier, M., Aubert, A., Séré, A., Lucas, C., Laforest, G., Helbling, J.-C., Tremblay, M.-E., Cota, D., Moisan, M.-P., Marsicano, G., Layé, S., Nadjar, A., 2021. Microglial cannabinoid type 1 receptor regulates brain inflammation in a sex-specific manner. *Cannabis Cannabinoid Res.* 6, 488–507. <https://doi.org/10.1089/can.2020.0170>.
- de San, González, Román, E., Llorente-Ovejero, A., Martínez-Gardeazabal, J., Moreno-Rodríguez, M., Giménez-Llort, L., Manuel, I., Rodríguez-Puertas, R., 2021. Modulation of neurolipid signaling and specific lipid species in the triple transgenic mouse model of Alzheimer's disease. *Int. J. Mol. Sci.* 22, 12256. <https://doi.org/10.3390/ijms22212256>.
- Demetrius, L.A., Driver, J., 2013. Alzheimer's as a metabolic disease. *Biogerontology* 14, 641–649. <https://doi.org/10.1007/s10522-013-9479-7>.
- Denovan-Wright, E.M., Robertson, H.A., 2000. Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. *Neuroscience* 98, 705–713. [https://doi.org/10.1016/s0306-4522\(00\)00157-3](https://doi.org/10.1016/s0306-4522(00)00157-3).
- Di Marzo, V., Hill, M.P., Bisogno, T., Crossman, A.R., Brotchie, J.M., 2000. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. *FASEB J.* 14, 1432–1438. <https://doi.org/10.1096/fj.14.10.1432>.
- Dos Santos, R.G., Hallak, J.E.C., Crippa, J.A.S., 2021. Neuropharmacological effects of the main phytochemicals: a narrative review. *Adv. Exp. Med. Biol.* 1264, 29–45. [https://doi.org/10.1007/978-3-030-57369-0\\_3](https://doi.org/10.1007/978-3-030-57369-0_3).
- Dowie, M.J., Bradshaw, H.B., Howard, M.L., Nicholson, L.F.B., Faull, R.L.M., Hannan, A.J., Glass, M., 2009. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease. *Neuroscience* 163, 456–465. <https://doi.org/10.1016/j.neuroscience.2009.06.014>.
- Durkee, C.A., Covel, A., Lines, J., Kofuji, P., Aguilar, J., Araque, A., 2019. Gi/o protein-coupled receptors inhibit neurons but activate astrocytes and stimulate gliotransmission. *Glia* 67, 1076–1093. <https://doi.org/10.1002/glia.23589>.
- Eraso-Pichot, A., Brasó-Vives, M., Golbano, A., Menacho, C., Claro, E., Galea, E., Masgrau, R., 2018. GSEA of mouse and human mitochondriomes reveals fatty acid oxidation in astrocytes. *Glia* 66, 1724–1735. <https://doi.org/10.1002/glia.23330>.
- Eraso-Pichot, A., Pouvreau, S., Olivera-Pinto, A., Gomez-Sotres, P., Skupio, U., Marsicano, G., 2023. Endocannabinoid signaling in astrocytes. *Glia* 71, 44–59. <https://doi.org/10.1002/glia.24246>.
- Farkas, S., Nagy, K., Palkovits, M., Kovács, G.G., Jia, Z., Donohue, S., Pike, V., Hallidin, C., Máthé, D., Harkany, T., Gulyás, B., Csiba, L., 2012. [125I]SD-7015 reveals fine modalities of CB1 cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer's disease. *Neurochem. Int.* 60, 286–291. <https://doi.org/10.1016/j.neuint.2011.11.004>.

- Fernández-Suárez, D., Celorrio, M., Riezu-Boj, J.I., Ugarte, A., Pacheco, R., González, H., Oyarzabal, J., Hillard, C.J., Franco, R., Aymerich, M.S., 2014. Monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model. *Neurobiol. Aging* 35, 2603–2616. <https://doi.org/10.1016/j.neurobiolaging.2014.05.021>.
- Ferreira, I.L., Resende, R., Ferreira, E., Rego, A.C., Pereira, C.F., 2010. Multiple defects in energy metabolism in Alzheimer's disease. *Curr. Drug Targets* 11, 1193–1206. <https://doi.org/10.2174/1389450111007011193>.
- Fillit, H., Green, A., 2021. Aducanumab and the FDA — where are we now? *Nat. Rev. Neurol.* 17, 129–130. <https://doi.org/10.1038/s41582-020-00454-9>.
- Fisher, D.W., Bennett, D.A., Dong, H., 2018. Sexual dimorphism in predisposition to Alzheimer's disease. *Neurobiol. Aging* 70, 308–324. <https://doi.org/10.1016/j.neurobiolaging.2018.04.004>.
- Fonseca, B.M., Rebelo, I., 2022. Cannabis and cannabinoids in reproduction and fertility: where we stand. *Reprod. Sci.* 29, 2429–2439. <https://doi.org/10.1007/s43032-021-00588-1>.
- Fraguas-Sánchez, A.I., Torres-Suárez, A.I., 2018. Medical use of cannabinoids. *Drugs* 78, 1665–1703. <https://doi.org/10.1007/s40265-018-0996-1>.
- Gangwani, M.R., Soto, J.S., Jami-Alahmadi, Y., Tiwari, S., Kawaguchi, R., Wohlschlegel, J.A., Khakh, B.S., 2023. Neuronal and astrocytic contributions to Huntington's disease dissected with zinc finger protein transcriptional repressors. *Cell Rep.* 42, 111953. <https://doi.org/10.1016/j.celrep.2022.111953>.
- Gaoni, Y., Mechoulam, R., 1964. Isolation, structure, and partial synthesis of an active constituent of hashish. *J. Am. Chem. Soc.* 86, 1646–1647. <https://doi.org/10.1021/ja01062a046>.
- García-Arencibia, M., García, C., Kurz, A., Rodríguez-Navarro, J.A., Gispert-Sánchez, S., Mena, M.A., Auburger, G., de Yébenes, J.G., Fernández-Ruiz, J., 2009. Cannabinoid CB1 receptors are early downregulated followed by a further upregulation in the basal ganglia of mice with deletion of specific park genes. *J. Neural Transm. Suppl.* 269–275. [https://doi.org/10.1007/978-3-211-92660-4\\_22](https://doi.org/10.1007/978-3-211-92660-4_22).
- GBD 2016 Dementia Collaborators, 2019. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the global burden of disease study 2016. *Lancet Neurol.* 18, 88–106. [https://doi.org/10.1016/S1474-4422\(18\)30403-4](https://doi.org/10.1016/S1474-4422(18)30403-4).
- Glass, M., Faull, R.L.M., Dragunow, M., 1993. Loss of cannabinoid receptors in the substantia nigra in huntington's disease. *Neuroscience* 56, 523–527. [https://doi.org/10.1016/0306-4522\(93\)90352-G](https://doi.org/10.1016/0306-4522(93)90352-G).
- Glass, M., Dragunow, M., Faull, R.L.M., 2000. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA receptor alterations in the human basal ganglia in Huntington's disease. *Neuroscience* 97, 505–519. [https://doi.org/10.1016/S0306-4522\(00\)00008-7](https://doi.org/10.1016/S0306-4522(00)00008-7).
- González, S., Scorticati, C., García-Arencibia, M., de Miguel, R., Ramos, J.A., Fernández-Ruiz, J., 2006. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. *Brain Res.* 1073–1074, 209–219. <https://doi.org/10.1016/j.brainres.2005.12.014>.
- Gordon, E., Devinsky, O., 2001. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. *Epilepsia* 42, 1266–1272. <https://doi.org/10.1046/j.1528-1157.2001.19301.x>.
- Götz, J., Bodea, L.-G., Goedert, M., 2018. Rodent models for Alzheimer disease. *Nat. Rev. Neurosci.* 19, 583–598. <https://doi.org/10.1038/s41583-018-0054-8>.
- Grafton, S.T., Mazzotta, J.C., Pahl, J.J., St George-Hyslop, P., Haines, J.L., Gusella, J., Hoffman, J.M., Baxter, L.R., Phelps, M.E., 1992. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. *Arch. Neurol.* 49, 1161–1167. <https://doi.org/10.1001/archneur.1992.00530350075022>.
- Gubellini, P., Picconi, B., Bari, M., Battista, N., Calabresi, P., Centonze, D., Bernardi, G., Finazzi-Agrò, A., Maccarrone, M., 2002. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. *J. Neurosci.* 22, 6900–6907. <https://doi.org/10.1523/JNEUROSCI.22-16-06900.2002>.
- Gutiérrez-Rodríguez, A., Bonilla-Del Río, I., Puente, N., Gómez-Urquijo, S.M., Fontaine, C.J., Egaña-Huguet, J., Elezgarai, I., Ruehle, S., Lutz, B., Robin, L.M., Soria-Gómez, E., Bellocchio, L., Padwal, J.D., van der Stelt, M., Mendizabal-Zubiaga, J., Reguero, L., Ramos, A., Gerrikagoitia, I., Marsicano, G., Grandes, P., 2018. Localization of the cannabinoid type-1 receptor in subcellular astrocyte compartments of mutant mouse hippocampus. *Glia* 66, 1417–1431. <https://doi.org/10.1002/glia.23314>.
- Han, J., Kesner, P., Metna-Laurent, M., Duan, T., Xu, L., Georges, F., Koehl, M., Arous, D.N., Mendizabal-Zubiaga, J., Grandes, P., Liu, Q., Bai, G., Wang, W., Xiong, L., Ren, W., Marsicano, G., Zhang, X., 2012. Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. *Cell* 148, 1039–1050. <https://doi.org/10.1016/j.cell.2012.01.037>.
- Hebert-Chatelain, E., Reguero, L., Puente, N., Lutz, B., Chauloff, F., Rossignol, R., Piazza, P.-V., Benard, G., Grandes, P., Marsicano, G., 2014. Cannabinoid control of brain bioenergetics: exploring the subcellular localization of the CB1 receptor. *Mol. Metab.* 3, 495–504. <https://doi.org/10.1016/j.molmet.2014.03.007>.
- Hebert-Chatelain, E., Desprez, T., Serrat, R., Bellocchio, L., Soria-Gomez, E., Busquets-García, A., Pagano Zottola, A.C., Delamarre, A., Cannich, A., Vincent, P., Varilh, M., Robin, L.M., Terral, G., García-Fernández, M.D., Colavita, M., Mazier, W., Drago, F., Puente, N., Reguero, L., Elezgarai, I., Dupuy, J.-W., Cota, D., Lopez-Rodriguez, M.-L., Barreda-Gómez, G., Massa, F., Grandes, P., Bénard, G., Marsicano, G., 2016. A cannabinoid link between mitochondria and memory. *Nature* 539, 555–559. <https://doi.org/10.1038/nature20127>.
- Heneka, M.T., Carson, M.J., El Khoury, J., Landreth, G.E., Brosseron, F., Feinstein, D.L., Jacobs, A.H., Wyss-Coray, T., Vitorica, J., Ransohoff, R.M., Herrup, K., Frautschy, S. A., Finsen, B., Brown, G.C., Verkhratsky, A., Yamanaka, K., Koistinaho, J., Latz, E., Halle, A., Petzold, G.C., Town, T., Morgan, D., Shinohara, M.L., Perry, V.H., Holmes, C., Bazan, N.G., Brooks, D.J., Hunot, S., Joseph, B., Deigendesch, N., Garaschuk, O., Boddeke, E., Dinarello, C.A., Breitner, J.C., Cole, G.M., Golenbock, D. T., Kummer, M.P., 2015. Neuroinflammation in Alzheimer's disease. *Lancet Neurol.* 14, 388–405. [https://doi.org/10.1016/S1474-4422\(15\)70016-5](https://doi.org/10.1016/S1474-4422(15)70016-5).
- Hippius, H., Neundörfer, G., 2003. The discovery of Alzheimer's disease. *Dialogues Clin. Neurosci.* 5, 101–108.
- Hong, C., Jeong, B., Park, H.J., Chung, J.Y., Lee, J.E., Kim, J., Shin, Y.-C., So, I., 2020. TRP channels as emerging therapeutic targets for neurodegenerative diseases. *Front. Physiol.* 11, 238. <https://doi.org/10.3389/fphys.2020.00238>.
- Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S.G., Croteau, D.L., Bohr, V.A., 2019. Ageing as a risk factor for neurodegenerative disease. *Nat. Rev. Neurol.* 15, 565–581. <https://doi.org/10.1038/s41582-019-0244-7>.
- Howlett, A.C., 2002. The cannabinoid receptors. *Prostaglandins Other Lipid Mediat.* 68–69, 619–631. [https://doi.org/10.1016/S0090-6980\(02\)00060-6](https://doi.org/10.1016/S0090-6980(02)00060-6).
- Hurley, M.J., Mash, D.C., Jenner, P., 2003. Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain. *J. Neural Transm. (Vienna)* 110, 1279–1288. <https://doi.org/10.1007/s00702-003-0033-7>.
- Iannotti, F.A., Di Marzo, V., Petrosino, S., 2016. Endocannabinoids and endocannabinoid-related mediators: targets, metabolism and role in neurological disorders. *Prog. Lipid Res.* 62, 107–128. <https://doi.org/10.1016/j.plipres.2016.02.002>.
- Jiao, S.-S., Bu, X.-L., Liu, Y.-H., Zhu, C., Wang, Q.-H., Shen, L.-L., Liu, C.-H., Wang, Y.-R., Yao, X.-Q., Wang, Y.-J., 2016. Sex dimorphism profile of Alzheimer's disease-type pathologies in an APP/PS1 mouse model. *Neurotox. Res.* 29, 256–266. <https://doi.org/10.1007/s12640-015-9589-x>.
- Jimenez-Blasco, D., Busquets-García, A., Hebert-Chatelain, E., Serrat, R., Vicente-Gutierrez, C., Ioannidou, C., Gómez-Sotres, P., Lopez-Fabuel, I., Resch-Beuser, M., Resel, E., Arnouil, D., Saraswat, D., Varilh, M., Cannich, A., Julio-Kalajic, F., Bonilla-Del Río, I., Almeida, A., Puente, N., Achicallende, S., Lopez-Rodriguez, M.-L., Jollé, C., Déglon, N., Pellerin, L., Josephine, C., Bonvento, G., Panatier, A., Lutz, B., Piazza, P.-V., Guzmán, M., Bellocchio, L., Bouziers-Sore, A.-K., Grandes, P., Bolaños, J.P., Marsicano, G., 2020. Glucose metabolism links astroglial mitochondria to cannabinoid effects. *Nature* 583, 603–608. <https://doi.org/10.1038/s41586-020-2470-y>.
- Jung, K.-M., Astarita, G., Yasar, S., Vasilevko, V., Cribbs, D.H., Head, E., Cotman, C.W., Piomelli, D., 2012. An amyloid  $\beta$ 42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease. *Neurobiol. Aging* 33, 1522–1532. <https://doi.org/10.1016/j.neurobiolaging.2011.03.012>.
- Kalifa, S., Polston, E.K., Allard, J.S., Manay, K.F., 2011. Distribution patterns of cannabinoid CB1 receptors in the hippocampus of APPsw/PS1 $\Delta$ E9 double transgenic mice. *Brain Res.* 1376, 94–100. <https://doi.org/10.1016/j.brainres.2010.12.061>.
- Kammaté, A., Sirisín, J., Watanabe, M., Kondo, H., Hipkaeo, W., Chomphoo, S., 2022. Mitochondrial localization of CB1 in progesterone-producing cells of ovarian interstitial glands of adult mice. *J. Histochem. Cytochem.* 70, 251–257. <https://doi.org/10.1369/00221554211063516>.
- Kano, M., Ohno-Shosaku, T., Hashimoto, Y., Uchigashima, M., Watanabe, M., 2009. Endocannabinoid-mediated control of synaptic transmission. *Physiol. Rev.* 89, 309–380. <https://doi.org/10.1152/physrev.00019.2008>.
- Kaplan, A., Stockwell, B.R., 2012. Therapeutic approaches to preventing cell death in Huntington disease. *Prog. Neurobiol.* 99, 262–280. <https://doi.org/10.1016/j.pneurobio.2012.08.004>.
- Kearn, C.S., Blake-Palmer, K., Daniel, E., Mackie, K., Glass, M., 2005. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? *Mol. Pharmacol.* 67, 1697–1704. <https://doi.org/10.1124/mol.104.006882>.
- Khan, S.S., Lee, F.J.S., 2014. Delineation of domains within the cannabinoid CB1 and dopamine D2 receptors that mediate the formation of the heterodimer complex. *J. Mol. Neurosci.* 53, 10–21. <https://doi.org/10.1007/s12031-013-0181-7>.
- Knopman, D.S., Amieva, H., Petersen, R.C., Chételat, G., Holtzman, D.M., Hyman, B.T., Nixon, R.A., Jones, D.T., 2021. Alzheimer disease. *Nat. Rev. Dis. Primers* 7, 33. <https://doi.org/10.1038/s41572-021-00269-y>.
- Koch, M., Varella, L., Kim, J.G., Kim, J.D., Hernandez-Nuno, F., Simonds, S.E., Castorena, C.M., Vianna, C.R., Elmquist, J.K., Morozov, Y.M., Rakic, P., Bechmann, I., Cowley, M.A., Sziget-Buck, K., Dietrich, M.O., Gao, X.-B., Diano, S., Horvath, T.L., 2015. Hypothalamic POMC neurons promote cannabinoid-induced feeding. *Nature* 519, 45–50. <https://doi.org/10.1038/nature14260>.
- Kumar, A., Ratan, R.R., 2016. Oxidative stress and Huntington's disease: the good, the bad, and the ugly. *J. Huntingtons Dis.* 5, 217–237. <https://doi.org/10.3233/JHD-160205>.
- Kuwert, T., Lange, H.W., Boecker, H., Titz, H., Herzog, H., Aulich, A., Wang, B.-C., Nayak, U., Feinendegen, L.E., 1993. Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease. *J. Neurol.* 241, 31–36. <https://doi.org/10.1007/BF00870669>.
- Laere, K.V., Casteels, C., Dhollander, I., Goffin, K., Grachev, I., Bormans, G., Vandenbergh, W., 2010. Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. *J. Nucl. Med.* 51, 1413–1417. <https://doi.org/10.2967/jnumed.110.077156>.
- Lastres-Becker, I., Berrendero, F., Lucas, J.J., Martín-Aparicio, E., Yamamoto, A., Ramos, J.A., Fernández-Ruiz, J.J., 2002. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease. *Brain Res.* 929, 236–242. [https://doi.org/10.1016/S0006-8993\(01\)03403-5](https://doi.org/10.1016/S0006-8993(01)03403-5).
- Lastres-Becker, I., Bizat, N., Boyer, F., Hantraye, P., Fernández-Ruiz, J., Brouillet, E., 2004. Potential involvement of cannabinoid receptors in 3-nitropropionic acid

- toxicity in vivo. *Neuroreport* 15, 2375–2379. <https://doi.org/10.1097/00001756-200410250-00015>.
- Laurikainen, H., Tuominen, L., Tikka, M., Merisaari, H., Armio, R.-L., Sormunen, E., Borgana, F., Veronese, M., Howes, O., Haaparanta-Solin, M., Solin, O., Hietala, J., METSY group, 2019. Sex difference in brain CB1 receptor availability in man. *Neuroimage* 184, 834–842. <https://doi.org/10.1016/j.neuroimage.2018.10.013>.
- Lee, J.H., Agacinski, G., Williams, J.H., Wilcock, G.K., Esiri, M.M., Francis, P.T., Wong, P. T.-H., Chen, C.P., Lai, M.K.P., 2010. Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex. *Neurochem. Int.* 57, 985–989. <https://doi.org/10.1016/j.neuint.2010.10.010>.
- Lee, H.-G., Wheeler, M.A., Quintana, F.J., 2022. Function and therapeutic value of astrocytes in neurological diseases. *Nat. Rev. Drug Discov.* 21, 339–358. <https://doi.org/10.1038/s41573-022-00390-x>.
- Li, J.Y., Popovic, N., Brundin, P., 2005. The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. *NeuroRx* 2, 447–464.
- Lin, C.H., Tallaksen-Greene, S., Chien, W.M., Cearley, J.A., Jackson, W.S., Crouse, A.B., Ren, S., Li, X.J., Albin, R.L., Detloff, P.J., 2001. Neurological abnormalities in a knock-in mouse model of Huntington's disease. *Hum. Mol. Genet.* 10, 137–144. <https://doi.org/10.1093/hmg/10.2.137>.
- López-Sendón Moreno, J.L., García Caldentey, J., Trigo Cubillo, P., Ruiz Romero, C., García Ribas, G., Alonso Arias, M.A.A., García de Yébenes, M.J., Tolón, R.M., Galve-Roperh, I., Sagredo, O., Valdeolivas, S., Resel, E., Ortega-Gutierrez, S., García-Bermejo, M.L., Fernández Ruiz, J., Guzmán, M., de Yébenes, García, Prous, J., 2016. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease. *J. Neurol.* 263, 1390–1400. <https://doi.org/10.1007/s00415-016-8145-9>.
- Maccarrone, M., Totaro, A., Leuti, A., Giacobbo, G., Scipioni, L., Mango, D., Coccorello, R., Nisticò, R., Oddi, S., 2018. Early alteration of distribution and activity of hippocampal type-1 cannabinoid receptor in Alzheimer's disease-like mice overexpressing the human mutant amyloid precursor protein. *Pharmacol. Res.* 130, 366–373. <https://doi.org/10.1016/j.phrs.2018.02.009>.
- Manuel, I., de San, González, Román, E., Giral, M.T., Ferrer, I., Rodríguez-Puertas, R., 2014. Type-1 cannabinoid receptor activity during Alzheimer's disease progression. *J. Alzheimers Dis.* 42, 761–766. <https://doi.org/10.3233/JAD-140492>.
- Marinelli, Sara, Marrone, M.C., Di Domenico, M., Marinelli, Silvia, 2023. Endocannabinoid signaling in microglia. *Glia* 71, 71–90. <https://doi.org/10.1002/glia.24281>.
- Martín, A.B., Fernandez-Espejo, E., Ferrer, B., Gorriti, M.A., Bilbao, A., Navarro, M., Rodríguez de Fonseca, F., Moratalla, R., 2008. Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. *Neuropsychopharmacology* 33, 1667–1679. <https://doi.org/10.1038/sj.npp.1301558>.
- Martín, R., Bajo-Graneras, R., Moratalla, R., Perea, G., Araque, A., 2015. Circuit-specific signaling in astrocyte-neuron networks in basal ganglia pathways. *Science* 349, 730–734. <https://doi.org/10.1126/science.1267945>.
- Martinez Ramirez, C.E., Ruiz-Pérez, G., Stollenwerk, T.M., Behlke, C., Doherty, A., Hillard, C.J., 2023. Endocannabinoid signaling in the central nervous system. *Glia* 71, 5–35. <https://doi.org/10.1002/glia.24280>.
- Maya-López, M., Colín-González, A.L., Aguilera, G., de Lima, M.E., Colpo-Ceolin, A., Rangel-López, E., Villeda-Hernández, J., Rembao-Bojórquez, D., Túnez, I., Luna-López, A., Lazzarini-Lechuga, R., González-Puertos, V.Y., Posadas-Rodríguez, P., Silva-Palacios, A., Königsberg, M., Santamaría, A., 2017. Neuroprotective effect of WIN55,212-2 against 3-nitropropionic acid-induced toxicity in the rat brain: involvement of CB1 and NMDA receptors. *Am. J. Transl. Res.* 9, 261–274.
- Mckean, N.E., Handley, R.R., Snell, R.G., 2021. A review of the current mammalian models of Alzheimer's disease and challenges that need to be overcome. *Int. J. Mol. Sci.* 22, 13168. <https://doi.org/10.3390/ijms222313168>.
- Medina-Vera, D., Rosell-Valle, C., López-Gamero, A.J., Navarro, J.A., Zambrana-Infantes, E.N., Rivera, P., Santín, L.J., Suarez, J., Rodríguez de Fonseca, F., 2020. Imbalance of endocannabinoid/lysophosphatidylinositol receptors marks the severity of Alzheimer's disease in a preclinical model: a therapeutic opportunity. *Biology (Basel)* 9, 377. <https://doi.org/10.3390/biology9110377>.
- Mendizabal-Zubiaga, J., Melsner, S., Benard, G., Ramos, A., Reguero, L., Arrabal, S., Elezgarai, I., Gerrikagoitia, I., Suarez, J., Rodríguez De Fonseca, F., Puente, N., Marsicano, G., Grandes, P., 2016. Cannabinoid CB1 receptors are localized in striated muscle mitochondria and regulate mitochondrial respiration. *Front. Physiol.* 7, 476. <https://doi.org/10.3389/fphys.2016.00476>.
- Merlini, M., Meyer, E.P., Ulmann-Schuler, A., Nitsch, R.M., 2011. Vascular  $\beta$ -amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcA $\beta$  mice. *Acta Neuropathol.* 122, 293–311. <https://doi.org/10.1007/s00401-011-0834-y>.
- Mi, Y., Qi, G., Vitali, F., Shang, Y., Raikes, A.C., Wang, T., Jin, Y., Brinton, R.D., Gu, H., Yin, F., 2023. Loss of fatty acid degradation by astrocytic mitochondria triggers neuroinflammation and neurodegeneration. *Nat. Metab.* 5, 445–465. <https://doi.org/10.1038/s42255-023-00756-4>.
- Mievis, S., Blum, D., Ledent, C., 2011. Worsening of Huntington disease phenotype in CB1 receptor knockout mice. *Neurobiol. Dis.* 42, 524–529. <https://doi.org/10.1016/j.nbd.2011.03.006>.
- Molina-Holgado, E., Esteban, P.F., Arevalo-Martin, Á., Moreno-Luna, R., Molina-Holgado, F., Garcia-Ovejero, D., 2023. Endocannabinoid signaling in oligodendroglia. *Glia* 71, 91–102. <https://doi.org/10.1002/glia.24180>.
- Mosconi, L., Mistur, R., Switalski, R., Tsui, W.H., Glodzik, L., Li, Y., Pirraglia, E., De Santi, S., Reisberg, B., Wisniewski, T., de Leon, M.J., 2009. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. *Eur. J. Nucl. Med. Mol. Imaging* 36, 811–822. <https://doi.org/10.1007/s00259-008-1039-z>.
- Mounsey, R.B., Mustafa, S., Robinson, L., Ross, R.A., Riedel, G., Pertwee, R.G., Teismann, P., 2015. Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. *Exp. Neurol.* 273, 36–44. <https://doi.org/10.1016/j.expneurol.2015.07.024>.
- Mueller, R.L., Ellingson, J.M., Bidwell, L.C., Bryan, A.D., Hutchison, K.E., 2021. Are the acute effects of THC different in aging adults? *Brain Sci.* 11, 590. <https://doi.org/10.3390/brainsci11050590>.
- Mulder, J., Zilberter, M., Pasquaré, S.J., Alpár, A., Schulte, G., Ferreira, S.G., Kófalvi, A., Martín-Moreno, A.M., Keimpema, E., Tanila, H., Watanabe, M., Mackie, K., Hortobágyi, T., de Ceballos, M.L., Harkany, T., 2011. Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. *Brain* 134, 1041–1060. <https://doi.org/10.1093/brain/awr046>.
- Navarrete, M., Araque, A., 2008. Endocannabinoids mediate neuron-astrocyte communication. *Neuron* 57, 883–893. <https://doi.org/10.1016/j.neuron.2008.01.029>.
- Navarrete, M., Araque, A., 2010. Endocannabinoids potentiate synaptic transmission through stimulation of astrocytes. *Neuron* 68, 113–126. <https://doi.org/10.1016/j.neuron.2010.08.043>.
- Newington, J.T., Harris, R.A., Cumming, R.C., 2013. Reevaluating metabolism in Alzheimer's disease from the perspective of the astrocyte-neuron lactate shuttle model. *J. Neurodegener. Dis.* 2013, e234572. <https://doi.org/10.1155/2013/234572>.
- O'Keefe, L., Simcocks, A.C., Hryciw, D.H., Mathai, M.L., McAinch, A.J., 2014. The cannabinoid receptor 1 and its role in influencing peripheral metabolism. *Diabetes Obes. Metab.* 16, 294–304. <https://doi.org/10.1111/dom.12144>.
- Oláh, A., Alam, M., Chéret, J., Kis, N.G., Hegyi, Z., Szöllösi, A.G., Vidali, S., Bíró, T., Paus, R., 2020. Mitochondrial energy metabolism is negatively regulated by cannabinoid receptor 1 in intact human epidermis. *Exp. Dermatol.* 29, 616–622. <https://doi.org/10.1111/exd.14110>.
- Ooms, M., Rietjens, R., Rangarajan, J.R., Vunckx, K., Valdeolivas, S., Maes, F., Himmelreich, U., Fernandez-Ruiz, J., Bormans, G., Van Laere, K., Casteels, C., 2014. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice. *Neurobiol. Aging* 35, 2858–2869. <https://doi.org/10.1016/j.neurobiolaging.2014.06.010>.
- Pacher, P., Batkai, S., Kunos, G., 2006. The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol. Rev.* 58, 389–462. <https://doi.org/10.1124/pr.58.3.2>.
- Paes-Colli, Y., Aguiar, A.F.L., Isaac, A.R., Ferreira, B.K., Campos, R.M.P., Trindade, P.M.P., de Melo Reis, R.A., Sampaio, L.S., 2022. Phytocannabinoids and cannabis-based products as alternative pharmacotherapy in neurodegenerative diseases: from hypothesis to clinical practice. *Front. Cell. Neurosci.* 16.
- Páez, J.A., Campillo, N.E., 2019. Innovative therapeutic potential of cannabinoid receptors as targets in Alzheimer's disease and less well-known diseases. *Curr. Med. Chem.* 26, 3300–3340. <https://doi.org/10.2174/0929867325666180226095132>.
- Pagano Zottola, A.C., Severi, I., Cannich, A., Ciofi, P., Cota, D., Marsicano, G., Giordano, A., Bellocchio, L., 2022. Expression of functional cannabinoid type-1 (CB1) receptor in mitochondria of white adipocytes. *Cells* 11, 2582. <https://doi.org/10.3390/cells11162582>.
- Palpagama, T.H., Waldvogel, H.J., Faull, R.L.M., Kwakowsky, A., 2019. The role of microglia and astrocytes in Huntington's disease. *Front. Mol. Neurosci.* 12, 258. <https://doi.org/10.3389/fnmol.2019.00258>.
- Parkinson, J., 2002. An essay on the shaking palsy. *JNP* 14, 223–236. <https://doi.org/10.1176/jnp.14.2.223>.
- Patricio-Martínez, A., Sánchez-Zavaleta, R., Angulo-Cruz, I., Gutiérrez-Praxedes, L., Ramírez, E., Martínez-García, I., Limón, I.D., 2019. The acute activation of the CB1 receptor in the hippocampus decreases neurotoxicity and prevents spatial memory impairment in rats lesioned with  $\beta$ -amyloid 25–35. *Neuroscience* 416, 239–254. <https://doi.org/10.1016/j.neuroscience.2019.08.001>.
- Piazza, P.V., Cota, D., Marsicano, G., 2017. The CB1 receptor as the cornerstone of exostasis. *Neuron* 93, 1252–1274. <https://doi.org/10.1016/j.neuron.2017.02.002>.
- Piomelli, D., 2003. The molecular logic of endocannabinoid signalling. *Nat. Rev. Neurosci.* 4, 873–884. <https://doi.org/10.1038/nrn1247>.
- Piro, J.R., Benjamin, D.L., Duerr, J.M., Pi, Y., Gonzales, C., Wood, K.M., Schwartz, J.W., Nomura, D.K., Samad, T.A., 2012. A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. *Cell Rep.* 1, 617–623. <https://doi.org/10.1016/j.celrep.2012.05.001>.
- Pisani, A., Fezza, F., Galati, S., Battista, N., Napolitano, S., Finazzi-Agrò, A., Bernardi, G., Brusa, L., Pierantozzi, M., Stanzione, P., Maccarrone, M., 2005. High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. *Ann. Neurol.* 57, 777–779. <https://doi.org/10.1002/ana.20462>.
- Pisani, V., Moschella, V., Bari, M., Fezza, F., Galati, S., Bernardi, G., Stanzione, P., Pisani, A., Maccarrone, M., 2010. Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients. *Mov. Disord.* 25, 920–924. <https://doi.org/10.1002/mds.23014>.
- Poewe, W., Seppi, K., Tanner, C.M., Halliday, G.M., Brundin, P., Volkman, J., Schrag, A.-E., Lang, A.E., 2017. Parkinson disease. *Nat. Rev. Dis. Primers* 3, 17013. <https://doi.org/10.1038/nrdp.2017.13>.
- Polyzos, A.A., Lee, D.Y., Datta, R., Hauser, M., Budworth, H., Holt, A., Mihalik, S., Goldschmidt, P., Frankel, K., Trego, K., Bennett, M.J., Vockley, J., Xu, K., Gratton, E., McMurray, C.T., 2019. Metabolic reprogramming in astrocytes distinguishes region-specific neuronal susceptibility in Huntington mice. *Cell Metab.* 29, 1258–1273.e11. <https://doi.org/10.1016/j.cmet.2019.03.004>.

- Ramírez, B.G., Blázquez, C., del Pulgar, T.G., Guzmán, M., de Ceballos, M.L., 2005. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. *J. Neurosci.* 25, 1904–1913. <https://doi.org/10.1523/JNEUROSCI.4540-04.2005>.
- Robin, L.M., Oliveira da Cruz, J.F., Langlais, V.C., Martín-Fernandez, M., Metna-Laurent, M., Busquets-García, A., Bellocchio, L., Soria-Gomez, E., Papouin, T., Varilh, M., Sherwood, M.W., Belluomo, I., Balcells, G., Matias, I., Bosier, B., Drago, F., Van Eckhaut, A., Smolders, I., Georges, F., Araque, A., Panatier, A., Oliet, S.H.R., Marsicano, G., 2018. Astroglial CB1 receptors determine synaptic D-serine availability to enable recognition memory. *Neuron* 98, 935–944.e5. <https://doi.org/10.1016/j.neuron.2018.04.034>.
- Rossato, M., Ion Popa, F., Ferigo, M., Clari, G., Foresta, C., 2005. Human sperm express cannabinoid receptor CB1, the activation of which inhibits motility, acrosome reaction, and mitochondrial function. *J. Clin. Endocrinol. Metab.* 90, 984–991. <https://doi.org/10.1210/jc.2004-1287>.
- Rubino, T., Parolaro, D., 2011. Sexually dimorphic effects of cannabinoid compounds on emotion and cognition. *Front. Behav. Neurosci.* 5, 64. <https://doi.org/10.3389/fnbeh.2011.00064>.
- Ruiz-Pérez, G., de Martín, Ruiz, Esteban, S., Marqués, S., Aparicio, N., Grande, M.T., Benito-Cuesta, I., Martínez-Relimpio, A.M., Arnanz, M.A., Tolón, R.M., Posada-Ayala, M., Cravatt, B.F., Esteban, J.A., Romero, J., Palenzuela, R., 2021. Potentiation of amyloid beta phagocytosis and amelioration of synaptic dysfunction upon FAAH deletion in a mouse model of Alzheimer's disease. *J. Neuroinflammation* 18, 223. <https://doi.org/10.1186/s12974-021-02276-y>.
- Saft, C., von Hein, S.M., Lücke, T., Thiels, C., Peball, M., Djamshidian, A., Heim, B., Seppi, K., 2018. Cannabinoids for treatment of dystonia in Huntington's disease. *J. Huntingtons Dis.* 7, 167–173. <https://doi.org/10.3233/JHD-170283>.
- Schousboe, A., Waagepetersen, H.S., Sonnewald, U., 2019. Astrocytic pyruvate carboxylation: status after 35 years. *J. Neurosci. Res.* 97, 890–896. <https://doi.org/10.1002/jnr.24402>.
- Serrat, R., Covelo, A., Kouskoff, V., Delcasso, S., Ruiz-Calvo, A., Chenouard, N., Stella, C., Blancard, C., Salin, B., Julio-Kalajzić, F., Cannich, A., Massa, F., Varilh, M., Deforges, S., Robin, L.M., De Stefani, D., Busquets-García, A., Gambino, F., Beyeler, A., Pouvreau, S., Marsicano, G., 2021. Astroglial ER-mitochondria calcium transfer mediates endocannabinoid-dependent synaptic integration. *Cell Rep.* 37, 110133. <https://doi.org/10.1016/j.celrep.2021.110133>.
- Sieradzian, K.A., Fox, S.H., Hill, M., Dick, J.P., Crossman, A.R., Brotchie, J.M., 2001. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. *Neurology* 57, 2108–2111. <https://doi.org/10.1212/wnl.57.11.2108>.
- Sierra, S., Luquin, N., Navarro-Otano, J., 2018. The endocannabinoid system in cardiovascular function: novel insights and clinical implications. *Clin. Auton. Res.* 28, 35–52. <https://doi.org/10.1007/s10286-017-0488-5>.
- Silverdale, M.A., McGuire, S., McInnes, A., Crossman, A.R., Brotchie, J.M., 2001. Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. *Exp. Neurol.* 169, 400–406. <https://doi.org/10.1006/exnr.2001.7649>.
- Simola, N., Morelli, M., Carta, A.R., 2007. The 6-hydroxydopamine model of Parkinson's disease. *Neurotox. Res.* 11, 151–167. <https://doi.org/10.1007/BF03033565>.
- Simpson, I.A., Chundu, K.R., Davies-Hill, T., Honer, W.G., Davies, P., 1994. Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. *Ann. Neurol.* 35, 546–551. <https://doi.org/10.1002/ana.410350507>.
- Solas, M., Francis, P.T., Franco, R., Ramirez, M.J., 2013. CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. *Neurobiol. Aging* 34, 805–808. <https://doi.org/10.1016/j.neurobiolaging.2012.06.005>.
- Soria-Gomez, E., Pagano Zottola, A.C., Mariani, Y., Desprez, T., Barresi, M., Bonilla-Del Río, I., Muguruza, C., Le Bon-Jego, M., Julio-Kalajzić, F., Flynn, R., Terral, G., Fernández-Moncada, I., Robin, L.M., Oliveira da Cruz, J.F., Corinti, S., Amer, Y.O., Goncalves, J., Varilh, M., Cannich, A., Redon, B., Zhao, Z., Lesté-Lasserre, T., Vincent, P., Tolentino-Cortes, T., Busquets-García, A., Puente, N., Bains, J.S., Hebert-Chatelain, E., Barreda-Gómez, G., Chaouloff, F., Lohman, A.W., Callado, L.F., Grandes, P., Baufreton, J., Marsicano, G., Bellocchio, L., 2021. Subcellular specificity of cannabinoid effects in striatonigral circuits. *Neuron* 109, 1513–1526.e11. <https://doi.org/10.1016/j.neuron.2021.03.007>.
- Stella, N., 2023. THC and CBD: similarities and differences between siblings. *Neuron*. <https://doi.org/10.1016/j.neuron.2022.12.022>. S0896-6273(22)01119-9.
- Stumm, C., Hiebel, C., Hanstein, R., Purrio, M., Nagel, H., Conrad, A., Lutz, B., Behl, C., Clement, A.B., 2013. Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer's disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition. *Neurobiol. Aging* 34, 2574–2584. <https://doi.org/10.1016/j.neurobiolaging.2013.05.027>.
- Takkinen, J.S., López-Picón, F.R., Kirjavainen, A.K., Pihlaja, R., Snellman, A., Ishizu, T., Löyttyniemi, E., Solin, O., Rinne, J.O., Haaparanta-Solin, M., 2018. [18F]FMPEP-d2 PET imaging shows age- and genotype-dependent impairments in the availability of cannabinoid receptor 1 in a mouse model of Alzheimer's disease. *Neurobiol. Aging* 69, 199–208. <https://doi.org/10.1016/j.neurobiolaging.2018.05.013>.
- Talarico, G., Trebbastoni, A., Bruno, G., de Lena, C., 2019. Modulation of the cannabinoid system: a new perspective for the treatment of the Alzheimer's disease. *Curr. Neuropharmacol.* 17, 176–183. <https://doi.org/10.2174/1570159X16666180702144644>.
- Terradillos, I., Bonilla-Del Río, I., Puente, N., Serrano, M., Mimenza, A., Lekunberri, L., Anaut-Lusar, I., Reguero, L., Gerrickoitia, I., de Martín, Ruiz, Esteban, S., Hillard, C. J., Grande, M.T., Romero, J., Elezgarai, I., Grandes, P., 2023. Altered glial expression of the cannabinoid 1 receptor in the subiculum of a mouse model of Alzheimer's disease. *Glia* 71, 866–879. <https://doi.org/10.1002/glia.24312>.
- Thanvi, B.R., Lo, T.C.N., 2004. Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. *Postgrad. Med. J.* 80, 452–458. <https://doi.org/10.1136/pgmj.2003.013912>.
- Túnez, I., Tasset, I., Pérez-De La Cruz, V., Santamaría, A., 2010. 3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington's disease: past, present and future. *Molecules* 15, 878–916. <https://doi.org/10.3390/molecules15020878>.
- Valdebenito, R., Ruminot, I., Garrido-Gerter, P., Fernández-Moncada, I., Forero-Quintero, L., Alegría, K., Becker, H.M., Deitmer, J.W., Barros, L.F., 2016. Targeting of astrocytic glucose metabolism by beta-hydroxybutyrate. *J. Cereb. Blood Flow Metab.* 36, 1813–1822. <https://doi.org/10.1177/0271678X15613955>.
- van der Stelt, M., Fox, S.H., Hill, M., Crossman, A.R., Petrosino, S., Di Marzo, V., Brotchie, J.M., 2005. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. *FASEB J.* 19, 1140–1142. <https://doi.org/10.1096/fj.04-3010fje>.
- Van Laere, K., Casteels, C., Lunsken, S., Goffin, K., Grachev, I.D., Bormans, G., Vandenberghe, W., 2012. Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo. *Neurobiol. Aging* 33. <https://doi.org/10.1016/j.neurobiolaging.2011.02.009>, 620.e1–8.
- Vasincu, A., Rusu, R.-N., Ababei, D.-C., Larion, M., Bild, W., Stanciu, G.D., Solcan, C., Bild, V., 2022. Endocannabinoid modulation in neurodegenerative diseases: in pursuit of certainty. *Biology (Basel)* 11, 440. <https://doi.org/10.3390/biology11030440>.
- Vidal-Palencia, L., Ramon-Duaso, C., González-Parra, J.A., Busquets-García, A., 2022. Gene expression analysis of the endocannabinoid system in presymptomatic APP/PS1 mice. *Front. Pharmacol.* 13, 864591. <https://doi.org/10.3389/fphar.2022.864591>.
- Walsh, D., Nelson, K.A., Mahmoud, F.A., 2003. Established and potential therapeutic applications of cannabinoids in oncology. *Support Care Cancer* 11, 137–143. <https://doi.org/10.1007/s00520-002-0387-7>.
- Walsh, S., Minich, K., Mackie, K., Gorman, A.M., Finn, D.P., Dowd, E., 2010. Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat. *Brain Res. Bull.* 81, 543–548. <https://doi.org/10.1016/j.brainresbull.2010.01.009>.
- Weber, B., Barros, L.F., 2015. The astrocyte: powerhouse and recycling center. *Cold Spring Harb. Perspect. Biol.* 7, a020396. <https://doi.org/10.1101/cshperspect.a020396>.
- Weise, C.M., Chen, K., Chen, Y., Kuang, X., Savage, C.R., Reiman, E.M., Alzheimer's Disease Neuroimaging Initiative, 2018. Left lateralized cerebral glucose metabolism declines in amyloid-β positive persons with mild cognitive impairment. *Neuroimage Clin.* 20, 286–296. <https://doi.org/10.1016/j.nicl.2018.07.016>.
- Wollner, H.J., Matchett, J.R., Levine, J., Loewe, S., 1942. Isolation of a physiologically active tetrahydrocannabinol from cannabis sativa resin. *J. Am. Chem. Soc.* 64, 26–29. <https://doi.org/10.1021/ja01253a008>.
- Woodhams, S.G., Sagar, D.R., Burston, J.J., Chapman, V., 2015. The role of the endocannabinoid system in pain. *Handb. Exp. Pharmacol.* 227, 119–143. [https://doi.org/10.1007/978-3-662-46450-2\\_7](https://doi.org/10.1007/978-3-662-46450-2_7).
- Yu, X., Taylor, A.M.W., Nagai, J., Golshani, P., Evans, C.J., Coppola, G., Khakh, B.S., 2018. Reducing astrocyte calcium signaling in vivo alters striatal microcircuits and causes repetitive behavior. *Neuron* 99, 1170–1187.e9. <https://doi.org/10.1016/j.neuron.2018.08.015>.
- Yu, X., Nagai, J., Marti-Solano, M., Soto, J.S., Coppola, G., Babu, M.M., Khakh, B.S., 2020. Context-specific striatal astrocyte molecular responses are phenotypically exploitable. *Neuron* 108, 1146–1162.e10. <https://doi.org/10.1016/j.neuron.2020.09.021>.
- Zou, S., Kumar, U., 2018. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. *Int. J. Mol. Sci.* 19, 833. <https://doi.org/10.3390/ijms19030833>.
- Zulfikar, S., Garg, P., Nieweg, K., 2019. Contribution of astrocytes to metabolic dysfunction in the Alzheimer's disease brain. *Biol. Chem.* 400, 1113–1127. <https://doi.org/10.1515/hsz-2019-0140>.